# EDGAR Filing Document

**Accession Number:** 0001596946
**File Stem:** 0000950170-23-002382
**Filing Date:** 2023-2
**Character Count:** 150622
**Document Hash:** 64288d81f6ddafca7780e823f9fbc0d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-002382.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0000950170-23-002382

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 68

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quotient Ltd
- **CENTRAL INDEX KEY:** 0001596946
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 264719797
- **STATE OF INCORPORATION:** Y9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36415
- **FILM NUMBER:** 23606944

**BUSINESS ADDRESS:**
- **STREET 1:** 28 ESPLANADE
- **CITY:** SAINT HELIER
- **STATE:** Y9
- **ZIP:** JE2 3QA
- **BUSINESS PHONE:** 41274832286

**MAIL ADDRESS:**
- **STREET 1:** 28 ESPLANADE
- **CITY:** SAINT HELIER
- **STATE:** Y9
- **ZIP:** JE2 3QA

?xml version="1.0" encoding="ASCII"? 10-Q

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM** 10-Q

------

**(Mark One)** 

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended** December 31, 2022

**OR** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the transition period from to** 

**Commission File Number** 001-36415

------

QUOTIENT LIMITED

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| Jersey**, Channel Islands** | Not Applicable |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| Business Park Terre Bonne**,**<br>Route de Crassier 13**,**<br>1262 Eysins**,** Switzerland | **Not Applicable** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

011-41**-**22-716-9800

(Registrant's telephone number, including area code)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

------

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of February 2, 2023, there were 4,035,013 Ordinary Shares, nil par value, of Quotient Limited outstanding.

------

**TABLE OF CONTENTS** 

---

| | |
|:---|:---|
|  | **Page** |
| [<u>PART I – FINANCIAL INFORMATION</u>](#part_i_financial_information) | 3 |
|  <br>[<u>Item 1. Financial Statements</u>](#item1financialstatements) | 3 |
|  <br>[<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item_2_managements_discussion_analysis_f) | 21 |
|  <br>[<u>Item 3. Reserved</u>](#item_3_reserved) | 28 |
|  <br>[<u>Item 4. Controls and Procedures</u>](#item3controlsandprocedures) | 28 |
|  <br>[<u>PART II – OTHER INFORMATION</u>](#partiiother_information) | 29 |
|  <br>[<u>Item 1. Legal Proceedings</u>](#item1legalproceedings) | 29 |
|  <br>[<u>Item 1A. Risk Factors</u>](#item_1a_risk_factors) | 29 |
|  <br>[<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 30 |
|  <br>[<u>Item 3. Defaults Upon Senior Securities</u>](#item3defaultsuponsenior) | 30 |
|  <br>[<u>Item 4. Mine Safety Disclosures</u>](#item_4_mine_safety_disclosures) | 30 |
|  <br>[<u>Item 5. Other Information</u>](#item5otherinformation) | 30 |
|  <br>[<u>Item 6. Exhibits</u>](#item_6_exhibits) | 30 |
| <br>[<u>Signatures</u>](#signatures) | 32 |

---

- i -

------

**Cautionary note regarding forward-looking statements** 

This Quarterly Report on Form 10-Q, and exhibits thereto, contains estimates, predictions, opinions, projections and other statements that may be interpreted as "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2: "Management's Discussion and Analysis of Financial Condition and Results of Operations" and are also contained elsewhere in this Quarterly Report. Forward-looking statements can be identified by words such as "strategy," "objective," "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate," "might," "design" and other similar expressions, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain, and are subject to numerous known and unknown risks and uncertainties.

Forward-looking statements include statements about:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the consummation of the Transaction (as defined in the Transaction Support Agreement), and its impact on our outstanding ordinary and preferred shares and outstanding options and warrants to acquire ordinary shares, which will be cancelled for no consideration or extinguished in connection with the Transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to obtain Bankruptcy Court approval with respect to motions or other requests made to the Bankruptcy Court;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effects of our bankruptcy proceedings on our liquidity or results of operations or business prospects;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effects of our bankruptcy proceedings on our business and the interests of various constituents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•increased levels of employee attrition during our bankruptcy proceedings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the length of time that we will operate under Chapter 11 protection;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the possibility that we may have to cease operations and liquidate our MosaiQ business if we are unable to obtain additional capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our liquidity constraints and the impacts of a potential event of default under our senior secured notes arising from a missed interest payment on the notes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our plans to shift our business strategy to focus in the near term exclusively on the development and commercialization of MosaiQ products for the autoimmune and allergy clinical diagnostics markets and implement significant cost reductions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•continued or worsening adverse conditions in the global economic and financial markets, inflationary concerns, economic slowdowns, and international hostilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our anticipated cash needs, including the adequacy of our available cash and investment balances relative to our forecasted cash requirements for the next 12 months, the limited availability of sources of funding, and our estimates regarding our capital requirements and capital expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business, financial condition and available liquidity of the uncertainty as to the timing and amount of future cash distributions by our investment funds in which we have remaining investments of approximately $18.6 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the continuing development, regulatory approval and commercialization of the MosaiQ™️ technology, or "MosaiQ", including the need to raise the funds needed for these activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the design of blood grouping and disease screening capabilities of MosaiQ, the potential for the expansion of MosaiQ into the larger clinical diagnostics market and the benefits of MosaiQ for both customers and patients

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•future demand for and customer adoption of MosaiQ, the factors that we believe will drive such demand and our ability to address such demand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expected profit margins for MosaiQ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the size of the market for MosaiQ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the regulation of MosaiQ by the U.S. Food and Drug Administration, or the FDA, or other regulatory bodies, or any unanticipated regulatory changes or scrutiny by such regulators;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•future plans for our conventional reagent products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the status of our future relationships with customers, suppliers, and regulators relating to our products;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•future demand for our conventional reagent products and our ability to meet such demand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to manage the risks associated with international operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•anticipated changes, trends and challenges in our business and the transfusion diagnostics market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the long-term impact on our business of the United Kingdom ceasing to be a member of the European Union;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effects of competition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the expected outcome or impact of arbitration or litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the status of our business relationship with Ortho.

You should also refer to the various factors identified in this and other reports filed by us with the Securities and Exchange Commission, or SEC, including but not limited to those discussed in the section entitled "Risk Factors" in this report and in our Annual Report on Form 10-K for the year ended March 31, 2022, for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Further, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represent our views only as of the date of this Quarterly Report. Subsequent events and developments may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.

 **Note Regarding Stock Splits**

Unless the context otherwise requires, in this Quarterly Report, all share and per share amounts related to our common stock give effect to our 1-for-40 reverse stock split effective November 2, 2022.

**Available Information** 

Access to our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to these reports filed with or furnished to the SEC, may be obtained through the investor section of our website at www.quotientbd.com as soon as reasonably practical after we electronically file or furnish these reports. We do not charge for access to and viewing of these reports. Information on our website, including in the investor section, is not part of this Quarterly Report on Form 10-Q or any of our other securities filings unless specifically incorporated herein or therein by reference. In addition, our filings with the SEC may be accessed through the SEC's website at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.

------

**PART I – FINANCIAL INFORMATION** 

**Item 1. Financial Statements** 

**CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)** 

(Expressed in thousands of U.S. Dollars — except for share data and per share data)

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2022** | **March 31,<br> 2022** |
| **ASSETS** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $11934 | $65059 |
| &nbsp;&nbsp;&nbsp;Short-term investments |  | 2626 |
| &nbsp;&nbsp;&nbsp;Trade accounts receivable, net | 6647 | 6272 |
| &nbsp;&nbsp;&nbsp;Inventories | 14327 | 22036 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 7587 | 5761 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | 40495 | 101754 |
| Restricted cash | 869 | 8744 |
| Long-term investments | 15580 | 15467 |
| Property and equipment, net | 29440 | 33242 |
| Operating lease right-of-use assets | 28014 | 29411 |
| Intangible assets, net | 435 | 520 |
| Deferred income taxes | 141 | 123 |
| Other non-current assets | 4352 | 4728 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $119326 | $193989 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $2813 | $4524 |
| &nbsp;&nbsp;&nbsp;Accrued compensation and benefits | 9414 | 8503 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 13017 | 15729 |
| &nbsp;&nbsp;&nbsp;Current portion of operating lease liability | 4046 | 3535 |
| &nbsp;&nbsp;&nbsp;Current portion of finance lease obligation | 341 | 537 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | 29631 | 32828 |
| Long-term debt, less current portion | 240288 | 233313 |
| Derivative liabilities | 41 | 13515 |
| Operating lease liability, less current portion | 27583 | 28753 |
| Finance lease obligation, less current portion | 136 | 388 |
| Deferred income taxes | 1849 | 1988 |
| Defined benefit pension plan obligation | 5370 | 4777 |
| 7% Cumulative redeemable preference shares | 23313 | 22525 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | 328211 | 338087 |
| Commitments and contingencies |  |  |
| **Shareholders' equity (deficit):** |  |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares (nil par value) 4,035,013 and 2,565,284 issued and outstanding at December 31, 2022 and March 31, 2022 respectively | 558639 | 540736 |
| &nbsp;&nbsp;&nbsp;Additional paid in capital | 48992 | 46399 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | 6644 | (6191) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (823160) | (725042) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total shareholders' equity (deficit)** | (208885) | (144098) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and shareholders' equity (deficit)** | $119326 | $193989 |

---

The accompanying notes form an integral part of these condensed consolidated financial statements.

------

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)**

(Expressed in thousands of U.S. Dollars — except for share data and per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter ended December 31,** | **Quarter ended December 31,** | **Nine months ended December 31,** | **Nine months ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **Revenue:** |  |  |  |  |
| Product sales | $9954 | $10172 | $27624 | $28497 |
| Other revenues |  |  |  | 231 |
| **Total revenue** | 9954 | 10172 | 27624 | 28728 |
| Cost of revenue | (3904) | (7928) | (31141) | (17579) |
| **Gross margin** | 6050 | 2244 | (3517) | 11149 |
| **Operating expenses:** |  |  |  |  |
| Sales and marketing | (3298) | (2878) | (10117) | (8011) |
| Research and development, net of government grants | (15909) | (13260) | (44316) | (42545) |
| General and administrative expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Compensation expense in respect of share<br> options and management equity incentives | (924) | (2319) | (2593) | (5546) |
| &nbsp;&nbsp;&nbsp;Other general and administrative expenses | (11470) | (15038) | (28534) | (32009) |
| Total general and administrative expense | (12394) | (17357) | (31127) | (37555) |
| **Total operating expense** | (31602) | (33495) | (85560) | (88111) |
| **Operating loss** | (25551) | (31251) | (89077) | (76962) |
| **Other income (expense):** |  |  |  |  |
| Interest expense, net | (8233) | (9559) | (9421) | (21914) |
| Other, net | 20591 | (3507) | 1011 | 677 |
| **Other income (expense), net** | 12358 | (13066) | (8410) | (21237) |
| **Loss before income taxes** | (13193) | (44317) | (97487) | (98199) |
| Provision for income taxes | (131) | (504) | (631) | (1019) |
| **Net loss** | $(13324) | $(44821) | $(98118) | $(99218) |
| **Other comprehensive income (loss):** |  |  |  |  |
| Change in fair value of effective portion of<br> foreign currency cash flow hedges | $— | $(37) | $— | $(380) |
| Change in unrealized gain on short-term investments | (50) |  | (24) | (193) |
| Foreign currency (loss) gain | (14359) | 788 | 12817 | 2798 |
| Provision for pension benefit obligation | 14 | 15 | 42 | 44 |
| **Other comprehensive income (loss), net** | (14395) | 766 | 12835 | 2269 |
| **Comprehensive loss** | $(27719) | $(44055) | $(85283) | $(96949) |
| Net loss available to ordinary shareholders - basic and diluted | $(13324) | $(44821) | $(98118) | $(99218) |
| Loss per share - basic and diluted | $(3.13) | $(17.55) | $(26.45) | $(39.03) |
| Weighted-average shares outstanding - basic and diluted | 4250698 | 2553179 | 3709021 | 2542394 |

---

The accompanying notes form an integral part of these condensed consolidated financial statements.

------

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (unaudited)** 

(Expressed in thousands of U.S. Dollars — except for share data)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Ordinary shares** | **Ordinary shares** | **Additional paid in** | **Accumulated<br> Other Comprehensive** | **Accumulated** | **Total Shareholders'** |
|  | **Shares** | **Amount** | **capital** | **Loss** | **Deficit** | **Equity (Deficit)** |
| **September 30, 2022** | 3396118 | $558639 | $48068 | $21039 | $(809836) | $(182090) |
| Issue of shares upon exercise of pre-funded warrants | 630273 |  |  |  |  |  |
| Issue of shares upon exercise of incentive share options and vesting of RSUs | 8622 |  |  |  |  |  |
| Net loss |  |  |  |  | (13324) | (13324) |
| Change in unrealized gain on short-term investments |  |  |  | (50) |  | (50) |
| Foreign currency loss |  |  |  | (14359) |  | (14359) |
| Provision for pension benefit obligation |  |  |  | 14 |  | 14 |
| Other comprehensive loss |  |  |  | (14395) |  | (14395) |
| Stock-based compensation |  |  | 924 |  |  | 924 |
| **December 31, 2022** | 4035013 | $558639 | $48992 | $6644 | $(823160) | $(208885) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Ordinary shares** | **Ordinary shares** | **Additional paid in** | **Accumulated<br> Other Comprehensive** | **Accumulated** | **Total Shareholders'** |
|  | **Shares** | **Amount** | **capital** | **Loss** | **Deficit** | **Equity (Deficit)** |
| **March 31, 2022** | 2565284 | $540736 | $46399 | $(6191) | $(725042) | $(144098) |
| Issue of shares and pre-funded warrants, net of issue costs of $2,097 | 811458 | 17903 |  |  |  | 17903 |
| Issue of shares upon exercise of pre-funded warrants | 630273 |  |  |  |  |  |
| Issue of shares upon exercise of incentive share options and vesting of RSUs | 27998 |  |  |  |  |  |
| Net loss |  |  |  |  | (98118) | (98118) |
| Change in unrealized gain on short-term investments |  |  |  | (24) |  | (24) |
| Foreign currency gain |  |  |  | 12817 |  | 12817 |
| Provision for pension benefit obligation |  |  |  | 42 |  | 42 |
| Other comprehensive loss |  |  |  | 12835 |  | 12835 |
| Stock-based compensation |  |  | 2593 |  |  | 2593 |
| **December 31, 2022** | 4035013 | $558639 | $48992 | $6644 | $(823160) | $(208885) |

---

The accompanying notes form an integral part of these condensed consolidated financial statements.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Ordinary shares** | **Ordinary shares** | **Additional paid in** | **Accumulated<br> Other Comprehensive** | **Accumulated** | **Total Shareholders'** |
|  | **Shares** | **Amount** | **capital** | **Loss** | **Deficit** | **Deficit** |
| **September 30, 2021** | 2539790 | $540733 | $41343 | $(13095) | $(654309) | $(85328) |
| Issue of shares upon exercise of incentive share options and vesting of RSUs | 1267 | (1) |  |  |  | (1) |
| Issue of Consent Shares associated with Senior Secured Note modification | 21711 |  | 2263 |  |  | 2263 |
| Net loss |  |  |  |  | (44821) | (44821) |
| Change in the fair value of foreign currency cash flow hedges |  |  |  | (37) |  | (37) |
| Change in unrealized gain on short-term investments |  |  |  |  |  |  |
| Foreign currency gain |  |  |  | 788 |  | 788 |
| Provision for pension benefit obligation |  |  |  | 15 |  | 15 |
| Other comprehensive loss |  |  |  | 766 |  | 766 |
| Stock-based compensation |  |  | 1511 |  |  | 1511 |
| **December 31, 2021** | 2562768 | $540732 | $45117 | $(12329) | $(699130) | $(125610) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Ordinary shares** | **Ordinary shares** | **Additional paid in** | **Accumulated<br> Other Comprehensive** | **Accumulated** | **Total Shareholders'** |
|  | **Shares** | **Amount** | **capital** | **Loss** | **Deficit** | **Deficit** |
| **March 31, 2021** | 2531610 | $540813 | $38116 | $(14598) | $(599912) | $(35581) |
| Issue of shares upon exercise of incentive share options and vesting of RSUs | 9447 | (81) |  |  |  | (81) |
| Issue of Consent Shares associated with Senior Secured Note modification | 21711 |  | 2263 |  |  | 2263 |
| Net loss |  |  |  |  | (99218) | (99218) |
| Change in the fair value of foreign currency cash flow hedges |  |  |  | (380) |  | (380) |
| Change in unrealized gain on short-term investments |  |  |  | (193) |  | (193) |
| Foreign currency gain |  |  |  | 2798 |  | 2798 |
| Provision for pension benefit obligation |  |  |  | 44 |  | 44 |
| Other comprehensive loss |  |  |  | 2269 |  | 2269 |
| Stock-based compensation |  |  | 4738 |  |  | 4738 |
| **December 31, 2021** | 2562768 | $540732 | $45117 | $(12329) | $(699130) | $(125610) |

---

The accompanying notes form an integral part of these condensed consolidated financial statements.

------

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)** 

(Expressed in thousands of U.S. Dollars)

---

| | | |
|:---|:---|:---|
|  | **Nine months ended December 31,** | **Nine months ended December 31,** |
|  | **2022** | **2021** |
| **OPERATING ACTIVITIES:** |  |  |
| **Net loss** | $(98118) | $(99218) |
| **Adjustments to reconcile net loss to net cash provided by operating activities:** |  |  |
| Depreciation, amortization and loss on disposal of fixed assets | 4285 | 5696 |
| Share-based compensation | 2593 | 4738 |
| Increase in deferred lease rentals | 922 | 505 |
| Swiss pension obligation | 624 | 493 |
| Amortization of debt discount, royalty, and unrealized foreign currency loss (gains) on debt | 12990 | 6377 |
| Impairment of investments | 1201 |  |
| Change in fair value of derivative instruments | (15647) | (3926) |
| Accrued preference share dividends | 788 | 788 |
| Provision for income taxes | 632 | 1109 |
| **Net change in assets and liabilities:** |  |  |
| Trade accounts receivable, net | (744) | (879) |
| Inventories | 6544 | (468) |
| Accounts payable and accrued liabilities | 2280 | (3805) |
| Accrued compensation and benefits | 1401 | (5239) |
| Other assets and liabilities | (8997) | (2344) |
| **Net cash used in operating activities** | (89246) | (96173) |
| **INVESTING ACTIVITIES:** |  |  |
| Increase in short-term investments |  | (4500) |
| Realization of short-term investments | 2612 | 51425 |
| Purchase of property and equipment | (1666) | (2282) |
| **Net cash from investing activities** | 946 | 44643 |
| **FINANCING ACTIVITIES:** |  |  |
| Repayment of finance leases | (450) | (528) |
| Proceeds from issuance of long-term debt | 10000 | 104222 |
| Debt issuance costs |  | (3732) |
| Repayment of long-term debt |  | (12083) |
| Proceeds from (cost of) issuance of ordinary shares and warrants | 17903 | (81) |
| **Net cash generated from financing activities** | 27453 | 87798 |
| Effect of exchange rate fluctuations on cash and cash equivalents | (153) | 2404 |
| Change in cash and cash equivalents | (61000) | 38672 |
| Beginning cash and cash equivalents | 73803 | 54697 |
| Ending cash and cash equivalents | $12803 | $93369 |
| Reconciliation of cash, cash equivalents and restricted cash: |  |  |
| Cash and cash equivalents | $11934 | $85060 |
| Restricted cash | $869 | $8309 |
| Total cash, cash equivalents and restricted cash | $12803 | $93369 |

---

The accompanying notes form an integral part of these condensed consolidated financial statements.

------

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

(Expressed in thousands of U.S. Dollars — except for share data and per share data, unless otherwise stated)

**Note 1. Description of Business and Basis of Presentation** 

**Description of Business** 

The principal activity of Quotient Limited (the "Company") and its subsidiaries (the "Group") is the development, manufacture and sale of products for the global transfusion and clinical diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide. Through our subsidiary Alba Bioscience Limited ("Alba"), we manufacture, distribute and sell conventional reagent products used primarily to identify blood group antigens and antibodies in donor and patient blood and to perform daily quality assurance testing for third-party blood grouping instrument platforms. For several years we have invested heavily in an innovative blood testing technology that we call MosaiQ. Since our initial public offering, our focus has been on developing our proprietary MosaiQ technology for use in blood grouping and donor disease screening, which is commonly referred to as transfusion diagnostics. More recently, we have explored MosaiQ's potential for use beyond transfusion diagnostics in the larger clinical diagnostics market. Specifically, as discussed in our periodic reports filed with the SEC, we recently shifted our focus to potential applications for MosaiQ in the autoimmune and allergy clinical diagnostics markets. Our Alba business is profitable. To date, our MosaiQ business has incurred substantial losses and we expect it will continue to incur losses unless and until it successfully commercializes one or more products.

**Updates on Liquidity, Financial Condition and Company Strategy**

On December 5, 2022 the Company entered into an agreement (together with all exhibits, annexes and schedules thereto, the "Transaction Support Agreement"), with (i) holders of all of its outstanding senior secured notes (the "Senior Secured Notes") issued under that certain Indenture, dated as of October 14, 2016 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the "Senior Secured Notes Indenture"), by and among the Company, the guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee, and (ii) holders of more than 99% of its convertible notes (the "Convertible Notes") issued under that certain Indenture, dated as of May 26, 2021 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the "Convertible Notes Indenture" and together with the Senior Secured Notes Indenture, the "Indentures"), by and among the Company, the guarantors party thereto, and Wilmington Savings Fund Society, FSB, as trustee (such holders of the Senior Secured Notes and Convertible Notes, collectively, the "Consenting Noteholders"), whereby the Consenting Noteholders have agreed to support a restructuring of the Company's balance sheet, which is intended to be effectuated pursuant to a set of transactions to be commenced by the Company (collectively, the "Transactions").

In connection with the Transactions, all of the Company's outstanding equity securities (including its ordinary shares, preferred shares, options and warrants) are expected to be extinguished and cancelled for either nominal or no consideration (in accordance with Jersey law). As a result of this, on December 12, 2022, the Company notified the Nasdaq Stock Market LLC of its intention to voluntarily withdraw its ordinary shares from listing on the Nasdaq Global Market. In order to implement the delisting, the Company filed a Form 25 with the Securities and Exchange Commission on December 22, 2022. The delisting of the Company's ordinary shares took effect no earlier than ten days after the date of that Form 25 filing. As a result of this voluntary delisting, the last full trading day of its ordinary shares on the Nasdaq Global Market was December 30, 2022. The Company does not intend to apply to list its ordinary shares on any other stock exchange or for quotation of its ordinary shares in any quotation medium. The Transactions are intended to reduce the Company's debt obligations and inject liquidity into the Company's business as necessary to effectuate its strategy shift.

Under the Transaction Support Agreement, the Company and the Consenting Noteholders have agreed to act in good faith to consummate the Transactions and have undertaken other customary commitments to one another. The Consenting Noteholders have also agreed to forbear from exercising, for so long as the Transaction Support Agreement is in full force and effect, any and all rights and remedies in contravention of the Transaction Support Agreement, which are or becomes available to them in respect of the Senior Secured Notes, the Convertible Notes or any other claims or interests in connection therewith.

The Transaction Support Agreement contains certain deadlines relating to the Transactions, which include deadlines (collectively, the "Milestones") related to implementing the Transactions either through (i) the filing of a petition for relief under chapter 11 of the U.S. Bankruptcy Code in order to effect a plan of reorganization (the "Plan") that implements a fully consensual restructuring (the "Consensual Transaction") or (ii) parallel creditor schemes of arrangements in England and Jersey (the "Fallback Scheme"), in each case as described in, and contemplated under, the Implementation Steps Memorandum attached to the Transaction Support Agreement as Exhibit B (the "Implementation Steps Memo"), as well as an outside date of May 1, 2023 for the consummation of a Consensual Transaction or Fallback Scheme (such date, the "Outside Date"). The Transaction Support Agreement provides that Requisite Consenting Noteholders (as defined below) can direct the Company to implement the Transactions via alternative implementation steps, subject to the Fiduciary Out (as defined below).

------

If the board of directors of the Company reasonably determines, after considering the advice of outside counsel, that taking certain actions, or refraining to take certain actions, is reasonably required for such board of directors to comply with its fiduciary duties (including if such actions would require expenditures in excess of the Company's available liquidity), the Transaction Support Agreement provides that such board of directors may elect not to take, or refrain to take, such actions (such election, the "Fiduciary Out"). The Company may terminate the Transaction Support Agreement upon, among other circumstances, uncured material breaches of the Transaction Support Agreement by a Consenting Noteholder or a determination by the board of directors of the Company that termination is required pursuant to the Fiduciary Out.

The Consenting Noteholders have termination rights that may, as a general matter, be exercised by (i) holders of the Senior Secured Notes holding at least a majority of the outstanding Senior Secured Notes and (ii) holders of the Convertible Notes holding at least a majority of the outstanding Convertible Notes, and, in the case of both subsection (i) and (ii), each of the Specified Noteholders (each as defined in the Transaction Support Agreement) (the holders in (i) and (ii) together, "Requisite Consenting Noteholders"), which termination rights include, among other circumstances, exercise of the Fiduciary Out by the Company, material breaches of the Transaction Support Agreement by the Company and the failure of the Company to meet any Milestone.

Under the terms of the Transaction Support Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The holders of the Senior Secured Notes have agreed to fund their commitment portion of $10 million of indebtedness (the "Bridge Notes") to the Company by no later than December 13, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Each noteholder under the Senior Secured Notes Indenture has agreed to exchange (i) such notes held by it (other than the Bridge Notes) for newly issued senior secured debt at a discount, and (ii) its Bridge Notes for newly issued senior secured debt at face value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Certain holders of Senior Secured Notes have also agreed to purchase an aggregate of $13 million in new common equity at a 35% discount to a total equity value of $50 million (the "Agreed Equity Value"). In addition, each such Senior Secured Noteholder will receive its applicable share of an aggregate of $20 million in new common equity at the Agreed Equity Value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The Consenting Holders who own Convertible Notes have agreed that their Convertible Notes shall be extinguished for no value, other than for the purchase right set forth immediately below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Such holders of Convertible Notes have agreed to purchase an aggregate of $28 million in new common equity at a 35% discount to the Agreed Equity Value. In addition, each such Convertible Noteholder will receive its applicable share of an aggregate of $30 million in new common equity at the Agreed Equity Value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The newly issued senior secured debt will be secured by a first lien on substantially the same collateral and assets as were subject to liens under the Senior Secured Notes Indenture. It will (i) mature 5 years (or, with the consent of holders of the Senior Secured Notes holding at least a majority of the outstanding Senior Secured Notes and each of the Specified Noteholders, 7 years) from the closing date and (ii) bear interest at a rate of 12% payable in kind for the first three years (or, with certain consent, two years) following the closing date, and thereafter payable in cash. The new senior secured debt will also provide for a mandatory repurchase with 100% of the net proceeds from certain sales, include covenants and events of default substantially similar to those existing under the Senior Secured Notes Indenture, and be redeemable at a price of 103% of the principal amount thereof, plus accrued and unpaid interest, for the first 2 years after issuance, and at par (plus accrued and unpaid interest) thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•All existing equity of the Company will be extinguished and cancelled for no consideration.

On January 9, 2023, the Company entered into an amended and restated transaction support agreement (together with all exhibits, annexes and schedules thereto, the "A&R TSA") with holders of all of its (i) outstanding Senior Secured Notes, by and among the Company, the guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee, and (ii) Convertible Notes issued under the Convertible Notes Indenture and together with the Senior Secured Notes Indenture, the "Indentures"), by and among the Company, the guarantors party thereto, and Wilmington Savings Fund Society, FSB, as trustee (such holders of the Senior Secured Notes and Convertible Notes, collectively, the "Consenting Noteholders").

The A&R TSA amends and restates in its entirety the transaction support agreement (the "Original TSA") entered into by the parties on December 5, 2022 and previously disclosed in the Company's Current Report on Form 8-K filed on December 7, 2022. The A&R TSA updates and modifies certain steps effectuating the transactions pursuant to which the Company will undergo a comprehensive restructuring of its balance sheet (collectively, the "Transactions"), removes references to the potential creditor schemes of arrangement in England, enhances the diligence available for the benefit of the Consenting Noteholders, provides for automatic termination (rather than termination only after receipt of written notice) upon certain events, and reduces the threshold of approval

------

necessary to extend certain milestones set forth in the A&R TSA. The A&R TSA is otherwise substantially the same as the Original TSA.

On January 9, 2023, Quotient Holdings Newco, LP ("Newco"), Quotient Holdings Finance Company Limited ("Finance Co"), Quotient Holdings Merger Company Limited ("Merger Co") and the Company entered into an omnibus transaction agreement (together with all exhibits, annexes and schedules thereto, the "Omnibus Transaction Agreement") with holders of all of its Convertible Notes issued under the Convertible Notes Indenture (the "Convertible Noteholders").

Pursuant to the Omnibus Transaction Agreement, the Convertible Noteholders agree to the deemed issuance of paid-in-kind notes on account of the November 2022 interest payment due in respect of the Convertible Notes, the deemed transfer of an equal amount of the Convertible Notes (the "Convertible Notes Transferred Principal") to Newco in exchange for Newco granting certain equity purchase rights to each of the Convertible Noteholders, the deemed transfer of the Convertible Notes Transferred Principal by Newco to Finance Co in exchange for the issuance of 99,999 ordinary shares of Finance Co to Newco, the deemed transfer of half of the Convertible Notes Transferred Principal by Finance Co to Merger Co in exchange for the issuance of 99,999 ordinary shares of Merger Co to Finance Co, and the deemed transfer of all of the Convertible Notes Transferred Principal from Finance Co and Merger Co to the Company in exchange for the issuance of 800,000 preference shares of the Company to Finance Co and 800,000 preference shares of the Company to Merger Co. After the transfer of the Convertible Notes Transferred Principal to the Company, the Convertible Notes Transferred Principal will be cancelled and extinguished.

On January 10, 2023, Quotient filed a voluntary petition for relief under chapter 11 of title 11 (the "Chapter 11 Case") of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"). The Company will continue to operate its business as a "debtor in possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The Company has filed a series of first day motions with the Bankruptcy Court that seek authorization to continue to conduct its business without interruption. These motions are designed primarily to minimize the effect of bankruptcy on the Company's operations. None of Quotient's subsidiaries intend to file voluntary petitions for relief under the Bankruptcy Code, and each of those subsidiaries expects to continue to operate its respective business in the ordinary course unaffected by the Chapter 11 Case. The bankruptcy filing was contemplated under the A&R TSA (referenced below and signed during the three months ended December 31, 2022) as part of a comprehensive restructuring to de-lever the Company's consolidated balance sheet by reducing debt by approximately $140 million and provide new cash for ongoing operations.

**Going Concern** 

Our ability to continue as a going concern is contingent upon the Company's ability to successfully implement a plan of reorganization in the Chapter 11 Case and to implement the steps outlined in the A&R TSA. Furthermore, even if our debts are discharged through such plan, we will need to raise additional funds through debt or equity financing or through the sales of rights or other assets to fund the Company's operations and its capital needs. As a result, there is substantial doubt that we will be able to continue as a going concern. See "Updates on Liquidity, Financial Condition and Company Strategy" above for additional details.

**Basis of Presentation** 

The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and are unaudited. In accordance with those rules and regulations, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements.

In November 2022, Quotient implemented a reverse stock split of its shares of common stock in a ratio of 1-for-40. The number of shares, loss per share amounts, repurchase price per share amounts, and Common stock and Additional paid-in capital balances have been retroactively adjusted for all periods presented in this Quarterly Report on Form 10-Q to give effect to the reverse stock split as if it occurred at the beginning of the first period presented. See Note 6 – Ordinary and Preference Shares for additional information.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all normal and recurring adjustments considered necessary to present fairly the financial position, results of operations, changes in shareholders' equity and cash flows for the interim periods presented. The March 31, 2022 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The financial statements should be read in conjunction with the audited consolidated financial statements at and for the year ended March 31, 2022 included in the Company's Annual Report on Form 10-K for the year then ended. The results of operations for the three and nine month period ended December 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending March 31, 2023 and any future period.

The Company has incurred net losses and negative cash flows from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $823.2 million as of December 31, 2022. At December 31, 2022, the Company had available cash,

------

cash equivalents, and investments of $27.5 million. Our investments include approximately $15.6 million of cash invested in a fund that has suspended redemptions.

As discussed above, under "Updates on Liquidity, Financial Condition and Company Strategy," there is substantial doubt about our ability to continue as a going concern.

**Use of Estimates** 

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes.

As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to further update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company's condensed consolidated financial statements.

**Note 2. Summary of Significant Accounting Policies** 

**Restricted Cash**

Restricted cash comprised $0 at December 31, 2022 and $8.0 million at March 31, 2022, held in a cash reserve account pursuant to the indenture governing the Company's Senior Secured Notes and $0.8 and $0.7 million held at December 31, 2022 and March 31, 2022, respectively, held in a restricted account as security for the property rental obligations of the Company's Swiss subsidiary.

**Concentration of Credit Risks and Other Uncertainties** 

The Company evaluated the investments in the CSAM managed funds for impairment, in accordance with ASC 321-10-35, Investments – Equity Securities, and determined that its investment in one of the funds was impaired. We recorded $0.0 million and $1.2 million in impairment expenses in the three and nine month periods ended December 31, 2022 related to litigation and administrative costs expected to be incurred by Credit Suisse which Credit Suisse communicated would be deducted from investor recoveries.

The Company views the liquidation of the supply chain finance funds as a fluid situation with a significant amount of valuation uncertainty. The Company will closely monitor the situation and in the event that new information is released that provides valuation clarity, it will evaluate the accounting implications accordingly. The Company believes, and has advised Credit Suisse, that any losses on the supply chain funds should be borne by Credit Suisse. The Company will pursue all available options to recoup the full amount of its investment in the supply chain funds prior to liquidation.

The Company's main financial institutions for banking operation held all of the Company's cash and cash equivalents as of December 31, 2022 and March 31, 2022.

**Revenue Recognition** 

In the three and nine month period ended December 31, 2022, revenue recognized from performance obligations related to prior periods was not material. Other than those described in Note 1 to the audited annual Consolidated Financial statements for the year ended March 31, 2022, there were no other material revenues to be recognized in future periods related to remaining performance obligations at December 31, 2022.

The Company's other significant accounting policies are described in Note 1 to the audited annual Consolidated Financial Statements for the year ended March 31, 2022 included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2022.

There have been no significant changes to these policies that have had a material impact on the Company's condensed consolidated financial statements and related notes.

**Recently Issued Pronouncements**

There are no recently issued accounting standards that are expected to have a material impact on our condensed consolidated financial statements.

------

**Note 3. Debt** 

Total debt comprises:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br>2022** | **March 31,<br>2022** |
| Senior Secured Notes | $146904 | $132917 |
| Debt discount, net of amortization | (12955) | (13854) |
| Deferred debt costs, net of amortization | (2126) | (2678) |
| Carrying value Senior Secured Notes | 131823 | 116385 |
| Royalty liability | 24938 | 40076 |
| Convertible Notes | 107494 | 105000 |
| Debt discount, net of amortization | (21303) | (24968) |
| Deferred debt costs, net of amortization | (2664) | (3180) |
| Carrying value Convertible Notes | 83527 | 76852 |
| Total Debt | $240288 | $233313 |

---

The Company's debt at December 31, 2022 and March 31, 2022 comprises the Senior Secured Notes, the royalty liability, and the Convertible Notes.

**Senior Secured Notes**

On October 14, 2016, the Company completed the private placement of up to $120 million aggregate principal amount of the Senior Secured Notes and entered into an indenture governing the Senior Secured Notes with the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent. The Company issued $84 million aggregate principal amount of the Senior Secured Notes on October 14, 2016 and an additional $36 million aggregate principal amount of the Senior Secured Notes on June 29, 2018. On December 18, 2018, the Company also completed certain amendments to the indenture governing the Senior Secured Notes. The amendments included an increase to the aggregate principal amount of Senior Secured Notes that can be issued under the indenture from $120 million to up to $145 million following the European CE Marking of the Company's initial MosaiQ IH Microarray. On April 30, 2019, the Company was notified that it had received the European CE Marking of the initial MosaiQ IH Microarray and, on May 15, 2019, the Company issued the additional $25 million of Senior Secured Notes.

The obligations of the Company under the indenture and the Senior Secured Notes are unconditionally guaranteed on a secured basis by the guarantors, which include all the Company's subsidiaries, and the indenture governing the Senior Secured Notes contains customary events of default. The Company and its subsidiaries must also comply with certain customary affirmative and negative covenants, including a requirement to maintain six-months of interest in a cash reserve account maintained with the collateral agent. Upon the occurrence of a Change of Control, subject to certain conditions, or certain Asset Sales (each, as defined in the indenture), holders of the Senior Secured Notes may require the Company to repurchase for cash all or part of their Senior Secured Notes at a repurchase price equal to 101% or 100%, respectively, of the principal amount of the Senior Secured Notes to be repurchased, plus accrued and unpaid interest to the date of repurchase.

Interest on the Senior Secured Notes accrues at a rate of 12% per annum and is payable semi-annually on April 15 and October 15 of each year commencing on April 15, 2017. On April 15, 2021, the Company made a $12.1 million principal payment on the Senior Senior Secured Notes. Additionally, principal payments were due on each April 15 and October 15 until April 15, 2024 pursuant to a fixed amortization schedule.

The Company paid $8.7 million of the total proceeds of the three issuances into the cash reserve account maintained with the collateral agent under the terms of the indenture. Following the April 15, 2021 repayment of the Senior Secured Notes the balance held in the cash reserve account was reduced to $8.0 million.

On October 13, 2021, the Company received consents from the Consenting Holders of its Senior Secured Notes issued pursuant to the Indenture, dated as of October 14, 2016 (as subsequently amended, the "Indenture"), by and among the Company, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent, to certain amendments to the indenture governing the Senior Secured Notes (the "Indenture Amendments") pursuant to the fourth supplemental indenture, dated as of October 13, 2021 (the "Fourth Supplemental Indenture").

The Indenture Amendments included an 18-month extension of the final maturity of the Senior Secured Notes to October 2025 and a revision of the Notes' principal amortization schedule. The Indenture Amendments also changed the redemption prices for Notes redeemed pursuant to the optional redemption provisions of the Indenture.

------

The Senior Secured Notes may be redeemed from and after October 14, 2021 at redemption prices beginning at 106% of par and declining over time to 100.0% for redemptions occurring from and after April 14, 2024.

The interest rate on the Senior Secured Notes and the financial and other covenants in the Indenture remained unchanged.

In consideration for the Consenting Holders' consents to the Indenture Amendments, the Company agreed among other things to issue them (i) an aggregate of 23,319 of the Company's ordinary shares, nil par value per share (the "Consent Shares") and (ii) 5-year warrants to purchase an aggregate of 46,100 of the Company's ordinary shares for $160 per share (the " 2021 Consent Warrants"). The Company filed a registration statement with the SEC covering resales of the Consent Shares and the shares issuable on exercise of the 2021 Consent Warrants. The fair value of Consent Shares not yet issued are included in accrued expenses and other current liabilities and the fair value of 2021 Consent Warrants is included in derivative liabilities within our condensed consolidated balance sheet. Changes in fair value are recognized within Other, net in the accompanying condensed consolidated financial statements.

On July 6, 2022, the Company received consents from the Consenting Holders of its Senior Secured Notes issued pursuant to the Indenture, dated as of October 14, 2016, by and among the Company, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent, to Indenture Amendments pursuant to the sixth supplemental indenture, dated as of July 6, 2022 (the "Sixth Supplemental Indenture").

The Sixth Supplemental Indenture includes a change to the amortization payment schedule of the Senior Secured Notes from requiring semi-annual payments ranging from $12.1 million to $24.2 million beginning in April 2023, to requiring quarterly payments of $2.5 million beginning on July 15, 2024 and ending on July 15, 2025, with the remaining principal balance due on October 15, 2025, which will reduce expected amortization payments by $93.0 million over the next 36 months prior to the payment of the remaining principal balance at maturity. It removes the requirement that we maintain a cash reserve account for the benefit of holders of the Senior Secured Notes, and adds a covenant that we maintain a minimum liquidity of at least $8.0 million, comprised of cash and certain other eligible investments, as of the end of each fiscal quarter. It provides that 40% of the net cash proceeds from a sale of all or a material portion of our Alba business, subject to certain exceptions, will be applied to repay Senior Secured Notes and the remaining 60% may be used by us to fund operating expenses, capital expenditures and other investments permitted by the Sixth Supplemental Indenture. We have also agreed that the holders of the Senior Secured Notes will be entitled to appoint an observer to our board of directors. In addition, the debt incurrence covenant in the indenture governing our Convertible Notes has been amended to reduce our ability to incur indebtedness under certain baskets by the amount of any repayment of the Senior Secured Notes as described above.

In consideration for the Consenting Holders' consents to the Indenture Amendments, the Company issued them 5-year warrants to purchase an aggregate of 212,364 of the Company's ordinary shares for $30 per share (''2022 Consent Warrants"). The Company also filed a registration statement with the SEC covering resales of the shares issuable on exercise of the 2022 Consent Warrants.

The new principal amortization schedule of the Senior Secured Notes is as follows:

---

| | |
|:---|:---|
| **Payment Date** | **Amount** |
| &nbsp;&nbsp;July 15, 2024 | $2500 |
| &nbsp;&nbsp;October 15, 2024 | 2500 |
| &nbsp;&nbsp;January 1, 2025 | 2500 |
| &nbsp;&nbsp;April 15, 2025 | 2500 |
| &nbsp;&nbsp;July 15, 2025 | 2500 |
| &nbsp;&nbsp;October 15, 2025 | The principal balance then outstanding |

---

On November 21, 2022, the Company received consents from the Consenting Holders of its Senior Secured Notes issued pursuant to the Indenture, dated as of October 14, 2016, by and among the Company, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent, to further amend the Indenture pursuant to the Eight Supplemental Indenture, dated as of November 21, 2022 (the "Eight Supplemental Indenture"). The Eight Supplemental Indenture has been executed by the Company, the Trustee and the other parties thereto and is in effect.

The Eighth Supplemental Indenture eliminates the Company's obligation under the Senior Secured Notes to make the interest payment otherwise due on October 15, 2022 in cash, and permit the Company instead to make such interest payment "in kind" by issuing new debt securities to the noteholders. The Eighth Supplemental Indenture allows the Company to issue and deliver further senior secured notes (the "Further SSNs") in an aggregate principal amount of $4.0 million to satisfy interest due on the Senior Secured Notes by way of payment in-kind. The Eighth Supplemental Indenture increases the permitted issuance amount under the Senior Secured Notes to $145.0 million plus the October 2022 Interest Amount (being $4.0 million).

The Company sought the amendments described above to allow the Company to preserve liquidity and avoid an event of default that would otherwise result from the Company's failure to make a cash interest payment on or before October 17, 2022.

------

On December 15, 2022, the Company received consents from all of the Consenting Holders of its Senior Secured Notes issued pursuant to the Indenture, dated as of October 14, 2016, by and among the Company, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent, to further amend the Indenture pursuant to the Ninth Supplemental Indenture, dated as of December 15, 2022 (the "Ninth Supplemental Indenture"). The Ninth Supplemental Indenture has been executed by the Company, the Trustee and the other parties thereto and is in effect.

Pursuant to the Ninth Supplemental Indenture, the Company issued and delivered Further SSNs in an aggregate principal amount of $10 million. The Further SSNs have the same terms as the SSNs, except that the Further SSNs have payment priority over other SSNs if any event of default occurs under the Indenture. So long as an event of default does not occur under the Indenture, the Further SSNs and the original SSNs are treated as a single class thereunder, including for purposes of directions provided to the Trustee, waivers, amendments, redemptions and offers to purchase, and rank on a parity basis in right of payment and security. If an event of default occurs under the Indenture, the Further SSNs will constitute a separate class under the Indenture, and will have payment priority over the original Secured Notes.

**Royalty liability**

In connection with the three issuances of the Senior Secured Notes as well as the December 2018 amendment of the related indenture, the Company has entered into royalty rights agreements, pursuant to which the Company has agreed to pay 3.4% of the aggregate net sales of MosaiQ instruments and consumables made in the donor testing market in the United States and the European Union. The royalties will be payable beginning on the date that the Company or its affiliates makes its first sale of MosaiQ consumables in the donor testing market in the European Union or the United States and will end on the last day of the calendar quarter in which the eighth anniversary of the first sale date occurs. The royalty rights agreements are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 "Debt" to be treated as debt. The royalty rights agreements are accounted for separately as freestanding financial instruments. Consideration received for the debt and royalty rights was allocated to each component on a relative fair value basis. The difference between the relative fair value of the royalty rights agreements and the principle on the Senior Secured Notes is accounted for as debt discount and amortized through non-cash interest expense over the life of the Senior Secured Notes. Estimating the future cash outflows under the royalty rights agreements requires the Company to make certain estimates and assumptions about future sales of MosaiQ products. These estimates of the magnitude and timing of MosaiQ sales are subject to significant variability due to the current status of development of MosaiQ products, and thus are subject to significant uncertainty. The decrease in value of the royalty rights agreement from $40.1 million at March 31, 2022 to $24.9 million December 31, 2022, is due to the Company's decision to prioritize the clinical portfolio, which is not subject to the royalty rights agreement, through at least calendar year 2025 which resulted in a reversal of all non-cash interest expense recognized to date for the royalty liability. The royalty liability will be held at the initial carrying amount unless the liability meets criteria necessary for debt extinguishment under ASC 405-20, Extinguishments of Liabilities or until estimated future cash outflows exceed the current carrying value which would result in additional interest expense to be recognized.

**Convertible Notes** 

On May 26, 2021 the Company issued $95.0 million aggregate principal amount of convertible senior notes and on June 2, 2021, the Company issued an additional $10.0 million aggregate principal amount of convertible senior notes in connection with the original $95.0 million (collectively the "Convertible Notes"). The Convertible Notes bear interest at an annual rate of 4.75%. The Convertible Notes will mature on May 26, 2026. Accrued interest of $0.6 million and $1.9 million is included in accrued expenses and other current liabilities in the accompanying condensed consolidated financial statements at December 31, 2022 and March 31, 2022 respectively.

At any time before the close of business on the second business day immediately before the maturity date, holders of the Convertible Notes can convert the Convertible Notes either in whole or in part into the Company's ordinary shares at an initial conversion rate of 176.3668 ordinary shares per $1,000 principal amount of the Convertible Notes, subject to customary anti-dilution adjustments.

The Convertible Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options ("ASC 470-20") and ASC 815-40, Contracts in Entity's Own Equity ("ASC 815-40"). Based upon the Company's analysis, it was determined the Convertible Notes contain embedded features that need to be separately accounted for as a derivative liability component. The proceeds received from the issuance of the convertible debt instruments were bifurcated and recorded as a liability within derivative liabilities in the consolidated balance sheet. The convertible loan derivative is measured at fair value and changes are recognized within the accompanying condensed consolidated financial statements within Other, net.

The Company incurred approximately $3.7 million of debt issuance costs relating to the issuance of the Convertible Notes, which were recorded as a reduction to the Convertible Notes on the consolidated balance sheet, none of the issuance costs were attributable to the derivative component. The debt issuance costs and the debt discount are being amortized and recognized as additional interest expense over the expected life of the Convertible Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Convertible Notes. The effective interest rate on the Convertible Notes is 12.9%. The total interest expense was $7.9 and $6.0 million with coupon interest of $3.7 and $3.0

------

million and the amortization of debt discount and issuance costs of $4.2 and $3.0 million, for the nine month periods ended December 31, 2022 and 2021, respectively. The total interest expense was $2.7 and $2.5 million with coupon interest of $1.3 and $1.3 million and the amortization of debt discount and issuance costs of $1.4 and $1.2 million, for the three month periods ended December 31, 2022 and 2021, respectively

On January 4, 2023, the Company received consents from the Consenting Holders of its Convertible Notes issued pursuant to the Indenture, dated as of May 26, 2021 (as subsequently amended, the "Indenture"), by and among the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee (the "Trustee"), to further amend the Indenture pursuant to the Fourth Supplemental Indenture, (the "Fourth Supplemental Indenture"). The Fourth Supplemental Indenture has been executed by the Company, the Trustee and the other parties thereto and is in effect.

Pursuant to the Fourth Supplemental Indenture, the Company issued and delivered further Convertible Notes (the "Further Convertible Notes") in an aggregate principal amount of $2.5 million issued hereunder as payment "in-kind" of (and in satisfaction of any obligation to make a cash payment in respect of) accrued interest on the Convertible Notes that is due and payable on the interest payment date occurring on November 15, 2022 pursuant to the terms of the Convertible Notes. The Further Convertible Notes have the same terms as the Convertible Notes and shall be treated as a single class, including for all purposes under the Indenture, including directions provided to the Trustee, waivers, amendments, redemptions and offers to purchase, conversion rights, and otherwise, and shall rank on a parity basis in right of payment.

The Company sought the amendments described above to issue Further Convertible Notes to satisfy any obligation to make a cash payment in respect of accrued interest on the Convertible Notes that is due and payable on the interest payment date occurring on November 15, 2022 pursuant to the terms of the Convertible Notes. As of December 31, 2022 the interest payment due on November 15, 2022, has been reclassified as long-term debt as a result of the Fourth Supplemental Indenture.

As mentioned in Note 1, pursuant to the Omnibus Transaction Agreement, the Convertible Noteholders agree to the deemed issuance of paid-in-kind notes on account of the November 2022 interest payment due in respect of the Convertible Notes, the deemed transfer of an equal amount of the Convertible Notes (the "Convertible Notes Transferred Principal") to Newco in exchange for Newco granting certain equity purchase rights to each of the Convertible Noteholders, the deemed transfer of the Convertible Notes Transferred Principal by Newco to Finance Co in exchange for the issuance of 99,999 ordinary shares of Finance Co to Newco, the deemed transfer of half of the Convertible Notes Transferred Principal by Finance Co to Merger Co in exchange for the issuance of 99,999 ordinary shares of Merger Co to Finance Co, and the deemed transfer of all of the Convertible Notes Transferred Principal from Finance Co and Merger Co to the Company in exchange for the issuance of 800,000 preference shares of the Company to Finance Co and 800,000 preference shares of the Company to Merger Co. After the transfer of the Convertible Notes Transferred Principal to the Company, the Convertible Notes Transferred Principal will be cancelled and extinguished.

**Note 4. Consolidated Balance Sheet Detail** 

**Inventory** 

The following table summarizes inventory by category for the dates presented:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br>2022** | **March 31,<br>2022** |
| Raw materials | $5271 | $10228 |
| Work in progress | 2648 | 7154 |
| Finished goods | 6408 | 4654 |
| Total inventories | $14327 | $22036 |

---

Inventory at December 31, 2022 included $1,611 of raw materials, $833 of work in progress and $3,413 of finished goods related to the MosaiQ project. Inventory at March 31, 2022, included $6,761 of raw materials, $4,252 of work in progress and $2,758 of finished goods related to the MosaiQ project. During the nine month period ended December 31, 2022, the Company recorded a write-off of $9.7 million in inventory and a $5.1 million write-off of prepaid assets related to the transfusion related MosaiQ assets. Included in other accrued expenses at December 31, 2022, is $140 of projected losses on firm purchase commitments recorded in other accrued expenses.

------

**Accrued expenses and other current liabilities** 

Accrued expenses and other current liabilities consist of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2022** | **March 31,<br> 2022** |
| Accrued legal and professional fees | $2426 | $1254 |
| Accrued interest | 4156 | 9235 |
| Goods received not invoiced | 1755 | 1304 |
| Accrued capital expenditure | 124 | 193 |
| Other accrued expenses | 4556 | 3743 |
| Total accrued expenses and other current liabilities | $13017 | $15729 |

---

**Note 5. Fair value measurement**

The following table summarizes the Company's assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| Pension plan assets(1) | $— | $26074 | $— | $26074 |
| Total assets measured at fair value | $— | $26074 | $— | $26074 |
| Liabilities: |  |  |  |  |
| Convertible loan derivatives(2) |  |  |  |  |
| Debt related Consent Warrants(3) |  | 41 |  | 41 |
| Debt related Consent Shares | 1 |  |  | 1 |
| Total liabilities measured at fair value | $1 | $41 | $— | $42 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31, 2022** | **March 31, 2022** | **March 31, 2022** | **March 31, 2022** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| Pension plan assets(1) | $— | $24778 | $— | $24778 |
| Total assets measured at fair value | $— | $24778 | $— | $24778 |
| Liabilities: |  |  |  |  |
| Convertible loan derivatives(2) |  | 11858 |  | 11858 |
| Debt related Consent Warrants(3) |  | 1657 |  | 1657 |
| Debt related Consent Shares | 77 |  |  | 77 |
| Total liabilities measured at fair value | $77 | $13515 | $— | $13592 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the AXA LLP Foundation Suisse Romande collective investment fund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The fair value of the Convertible loan derivatives has been determined by utilizing a single factor lattice model using market-based observable inputs such as historical share prices for Quotient Limited, interest rates derived from the U.S. Dollar Swap interest rate curve, credit spread, and implied volatility obtained from third party market price quotations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The fair value of the 2021 and 2022 Consent Warrants (collectively ''Consent Warrants''), has been determined by utilizing a Black-Scholes model using market-based observable inputs such as historical share prices for Quotient Limited, quotations for US treasury interest rates, and implied volatility obtained from third party market price quotations.

On March 12, 2021, the Company announced that two funds managed by CSAM in which the Company had invested an aggregate of approximately $110.35 million had suspended redemptions. The investments into these funds were made in accordance with the Company's investment policy of making individual investments with a minimum of an A rating from a leading credit-rating agency. Each fund holds short-term credit obligations of various obligors. According to a press release issued by CSAM, redemptions in the funds were suspended because "certain part of the Subfunds' assets is currently subject to considerable uncertainties with respect to their accurate valuation." CSAM subsequently began a liquidation of the funds. Pursuant to the liquidation, the Company has already received cash distributions of approximately $91.3 million. Credit Suisse has advised that the credit assets held by the funds are covered by insurance that potentially will be available to cover losses the funds would incur if any of the obligors on the funds' credit assets were to default.

------

On April 22, 2021, Credit Suisse published its FY 2021 Q1 press release with commentary related to the Credit Suisse Supply Chain Finance Investment Grade Fund and the Credit Suisse (Lux) Supply Chain Finance Fund. Notably, Credit Suisse indicated that investors in the funds should assume losses will be incurred. Additionally on April 4, 2022, Credit Suisse indicated in its Annual General Meeting that they expected that litigation will be necessary to reinforce claims against individual debtors and insurance companies and recovery is not expected to occur over the next 12 months for one of our funds. Therefore, we determined that one of our two funds should be classified as long-term as of March 31, 2022 and we have maintained the long-term classification of one of our funds as of December 31, 2022. On November 11, 2022, we received a $2.6 million cash payment from Credit Suisse related to the final liquidation of the Credit Suisse Supply Chain Finance Investment Grade Fund which was previously classified as a short-term investment in our condensed consolidated financial statements.

In the year-ended March 31, 2021, Credit Suisse's decision to liquidate funds in which the Company held investments served as a trigger to evaluate the investments for impairment and each quarter the Company evaluates information from Credit Suisse to determine whether there are further triggering events. Through March 31, 2022, the Company recorded $3.3 million in impairments associated with these funds. We recorded $1.2 million in impairment expenses in the nine period ended December 31, 2022 based on information shared by Credit Suisse to CSAM investors which included updated estimates of litigation provisions and administrative expenses incurred or to be incurred by Credit Suisse which Credit Suisse communicated would be deducted from investor recoveries. No impairment expense was recorded in the quarter ended December 31, 2022 or in the three or nine month periods ended December 31, 2021.

The Company views the liquidation of the supply chain finance funds as a fluid situation with a significant amount of valuation uncertainty. The Company will closely monitor the situation and in the event that new information is released that provides valuation clarity, it will evaluate the accounting implications accordingly. The Company believes, and has advised Credit Suisse, that any losses on the supply chain funds, including recovery costs, should be borne by Credit Suisse. The Company will pursue all available options to recoup the full amount of its investment in the supply chain funds prior to liquidation.

The total unrealized gains on the short-term investments were $213 and $275 in the nine month periods ended December 31, 2022 and December 31, 2021, respectively. The amount of these unrealized gains reclassified to earnings were $24 and $193 in the nine month periods ended December 31, 2022 and December 31, 2021, respectively.

**Note 6. Ordinary and Preference Shares** 

**Ordinary shares** 

The Company's issued and outstanding ordinary shares were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares Issued<br> and Outstanding** | **Shares Issued<br> and Outstanding** |  |
|  | **December 31,<br>2022** | **March 31,<br>2022** | **Par value** |
| Ordinary shares | 4035013 | 2565284 | $— |
| Total | 4035013 | 2565284 | $— |

---

On June 28, 2022, the Company issued 811,458 ordinary shares in a public offering of shares at $12.00 per share.

On May 20, 2022, the Company received notice from The NASDAQ Stock Market ("Nasdaq") that, because the closing bid price for the Company's ordinary shares has been below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Market and was granted an initial compliance period of 180 calendar days to regain compliance with the minimum bid requirement or until November 16, 2022. The Company effected a 1-for-40 reverse stock split on November 2, 2022 in an effort to meet this minimum average share price requirement. No fractional shares were issued in connection with the reverse stock split. All outstanding share amounts have been restated to reflect the impact of the reverse stock split.

On December 12, 2022, the Company notified the Nasdaq Stock Market LLC of its intention to voluntarily withdraw its ordinary shares from listing on the Nasdaq Global Market. In order to implement the delisting, the Company filed a Form 25 with the Securities and Exchange Commission on December 22, 2022. The delisting of the Company's ordinary shares took effect no earlier than ten days after the date of that Form 25 filing. As a result of this voluntary delisting, the last full trading day of its ordinary shares on the Nasdaq Global Market was December 30, 2022. The Company does not intend to apply to list its ordinary shares on any other stock exchange or for quotation of its ordinary shares in any quotation medium.

------

**Preference shares** 

The Company's issued and outstanding preference shares consist of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Shares Issued<br> and Outstanding** | **Shares Issued<br> and Outstanding** | **Liquidation<br>amount per share** | **Liquidation<br>amount per share** |
|  | **December 31,<br> 2022** | **March 31,<br>2022** | **December 31,<br>2022** | **March 31,<br>2022** |
| 7% Cumulative Redeemable<br> Preference shares | 666665 | 666665 | $34.97 | $33.79 |
| Total | 666665 | 666665 |  |  |

---

The 7% Cumulative Redeemable Preference shares were issued to Ortho-Clinical Diagnostics Finco S.A.R.L., an affiliate of Ortho on January 29, 2015 at a subscription price of $22.50 per share. These preference shares are redeemable at the request of the shareholder on the "Redemption Trigger Date" which is currently the date of the ninth anniversary of the date of issue of the preference shares, but the Company may further extend the redemption date in one year increments up to the tenth anniversary of the date of issue. Because the 7% Cumulative Redeemable Preference shares are redeemable at the option of the shareholders, they are shown as a liability in the unaudited condensed consolidated balance sheet.

**Note 7. Share-Based Compensation** 

The Company records share-based compensation expense in respect of options and restricted share units ("RSUs") issued under its share incentive plans. Share-based compensation expense amounted to $924 and $2,319 in the quarters ended December 31, 2022 and December 31, 2021, respectively, and $2,593 and $5,546 in the nine month periods ended December 31, 2022 and December 31, 2021, respectively. The decrease in expense recognized in the quarter and nine-month period ended December 31, 2022 compared to the prior year is due to an assessment that certain performance based RSU's previously deemed probable of vesting were no longer probable of vesting due to the shift in business strategy described in Note 1.

**Note 8. Income Taxes** 

A reconciliation of the income tax expense at the statutory rate to the provision for income taxes is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter ended<br> December 31** | **Quarter ended<br> December 31** | **Nine months ended<br> December 31** | **Nine months ended<br> December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| Income tax expense at statutory rate | $— | $— | $— | $— |
| Tax rate change |  |  |  | (335) |
| Foreign tax rate differential | 726 | 816 | 3452 | 2736 |
| Increase in valuation allowance against deferred<br> tax assets | (857) | (1320) | (4083) | (3420) |
| Provision for income tax | $(131) | $(504) | $(631) | $(1019) |

---

**Note 9. Defined Benefit Pension Plans** 

The Company's Swiss subsidiary has a fully insured pension plan managed by AXA LPP Foundation Suisse Romande. The costs of this plan were:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter ended<br> December 31** | **Quarter ended<br> December 31** | **Nine months ended<br> December 31** | **Nine months ended<br> December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| Employer service cost | $688 | $622 | $2094 | $1874 |
| Interest cost | 97 | 22 | 296 | 66 |
| Expected return on plan assets | (109) | (76) | (332) | (228) |
| Amortization of prior service credit | 14 | 14 | 42 | 44 |
| Amortization of net loss |  |  |  |  |
| Net pension cost | $690 | $582 | $2100 | $1756 |

---

The employer contributions for the nine month periods ended December 31, 2022 and 2021 were $1,475 and $1,263, respectively. The estimated employer contributions for the fiscal year ending March 31, 2023 are $1,948.

------

**Note 10. Net Loss Per Share** 

In accordance with Accounting Standards Codification Topic 260 "Earnings Per Share", basic earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus potential ordinary shares considered outstanding during the period, as long as the inclusion of such shares is not anti-dilutive. Potential ordinary shares consist of the incremental ordinary shares issuable upon the exercise of share options (using the treasury shares method), the warrants to acquire ordinary shares, the ordinary shares issuable upon vesting of the RSUs, and the ordinary shares issuable on conversion of Convertible Notes.

As disclosed in Note 6 – Ordinary and Preference Shares, the Company implemented a reverse stock split in a ratio of 1-for-40 effective on November 2, 2022. The below computations of loss per share reflect the number of common stock shares after consideration for the reverse stock split. All common share and loss per share amounts have been adjusted retrospectively to give effect to the reverse stock split as if it occurred at the beginning of the first period presented.

The following table sets forth the computation of basic and diluted loss per ordinary share:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter ended** | **Quarter ended** | **Nine months ended** | **Nine months ended** |
|  | **December 31** | **December 31** | **December 31** | **December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| **Numerator:** |  |  |  |  |
| Net loss available to ordinary shareholders - basic and diluted | $(13324) | $(44821) | $(98118) | (99218) |
| **Denominator:** |  |  |  |  |
| Weighted average ordinary shares outstanding | 3606107 | 2553179 | 3201051 | 2542394 |
| Assumed exercise of pre-funded warrants | 644591 |  | 507970 |  |
| Weighted-average shares outstanding - basic and diluted | 4250698 | 2553179 | 3709021 | 2542394 |
| Loss per share - basic and diluted | $(3.13) | $(17.55) | $(26.45) | $(39.03) |

---

During the quarter ended June 30, 2022, the Company issued 855,208 pre-funded warrants. Those not-yet-converted to ordinary shares are assumed to be exercised for the calculation of basic and diluted loss per share as the exercise price of $0.04 was deemed to be a non-substantive exercise price compared to the pre-funded cost of $11.96 per share and the fair value of our ordinary shares. These are treated as permanent equity for both basic and diluted earnings per share calculations. Pre-funded warrants are not included in shares outstanding in our statement of stockholders equity or balance sheet, however the proceeds have been included in the value of share capital therein.

The following table sets out the numbers of ordinary shares excluded from the above computation of earnings per share at December 31, 2022 and December 31, 2021 as their inclusion would have been anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2022** | **December 31,<br> 2021** |
| Ordinary shares issuable on conversion of Convertible Notes<br> at $226.80 per share | 462963 | 462963 |
| Restricted share units awarded | 116734 | 84088 |
| Ordinary shares issuable on exercise of options to purchase ordinary<br> shares | 73276 | 75199 |
| Ordinary shares issuable on exercise of warrants at $645.60 per share | 2788 | 2788 |
| Ordinary shares issuable on exercise of warrants at $375.00 per share | 1600 | 1600 |
| Ordinary shares issuable on exercise of 2021 Consent Warrants at $160.00 per share | 46101 | 46101 |
| Ordinary shares issuable on exercise of 2022 Consent Warrants at $30.00 per share | 212365 |  |
| Consent Shares not yet issued | 1608 | 1608 |
| Total | 917435 | 674346 |

---

------

**Note 11. Restructuring** 

As indicated in the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2022, filed November 14, 2022, the Board of Directors of the Company approved a change in strategy in which the Company would suspend its activities focused on the commercialization of its transfusion diagnostics products and would instead focus in the near term on development and commercialization of MosaiQ products for the autoimmune and allergy clinical diagnostics markets. As a result of this shift in strategy, the Company implemented a material reduction in its workforce by approximately 100 positions. The Company expects the Restructuring Plan to be substantially completed by the first quarter of calendar year 2023.

As a result of the Restructuring Plan, the Company incurred the following charges:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Quarter Ended** | **Quarter Ended** | **Nine months ended** | **Nine months ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **Cash restructuring charges:** |  |  |  |  |
| Severance and other personnel costs | $3094440 | $- | $3094440 | $- |
| Total cash charges | 3094440 | - | $3094440 | $- |

---

Severance and other personnel costs are reflected in our condensed consolidated statements of comprehensive loss for the quarter and nine months ended of December 31, 2023 within research and development, net of government grants $2.4 million, sales and marketing $0.3 million, and general and administrative expense of $0.4 million.

The following table presents a roll-forward of cash restructuring-related liabilities, which is included within Accrued compensation and benefits in the condensed consolidated balance sheets, as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Severance and other personnel costs** | **Professional fees and other related charges** | **Total restructuring charges** |
| Balance as of September 30, 2022 | $- | $- | $- |
| Charges | 3094440 |  | 3094440 |
| Cash payments |  |  |  |
| Balance as of December 31, 2022 | $3094440 |  | $3094440 |

---

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the corresponding section of our Annual Report on Form 10-K for the year ended March 31, 2022 filed with the SEC on June 28, 2022.

The information set forth and discussed below for the quarters ended December 31, 2022 and December 31, 2021 is derived from the condensed consolidated financial statements included under Part I, Item 1 "Financial Statements" above. The financial information set forth and discussed below is unaudited but includes all normal and recurring adjustments that our management considers necessary for a fair presentation of the financial position and the operating results and cash flows for those periods. Our results of operations for a particular quarter may not be indicative of the results that may be expected for other quarters or the entire year.

In addition to historical financial information, the following discussion contains forward looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report, and our Annual Report on Form 10-K for the year ended March 31, 2022, particularly in "Risk Factors."

**Overview** 

We were incorporated in Jersey, Channel Islands on January 18, 2012. On February 16, 2012, we acquired the entire issued share capital of Alba Bioscience Limited (or Alba), Quotient Biodiagnostics, Inc. (or QBDI) and QBD (QSIP) Limited (or QSIP) from Quotient Biodiagnostics Group Limited (or QBDG), our predecessor.

**Updates on Liquidity, Financial Condition and Company Strategy**

On January 10, 2023, Quotient filed a voluntary petition for relief under chapter 11 of title 11 (the "Chapter 11 Case") of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"). The Company will continue to operate its business as a "debtor in possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The Company has filed a series of first day motions with the Bankruptcy Court that seek authorization to continue to conduct its business without interruption. These motions are designed primarily to minimize the effect of bankruptcy on the Company's operations. None of Quotient's subsidiaries intend to file voluntary petitions for relief under the Bankruptcy Code, and each of those subsidiaries expects to continue to operate its respective business in the ordinary course unaffected by the Chapter 11 Case. The bankruptcy filing was contemplated under the A&R TSA as part of a comprehensive restructuring to de-lever the Company's consolidated balance sheet by reducing debt by approximately $140 million and provide new cash for ongoing operations. See Note 1 for additional information.

In an effort to sustain our business under current market conditions as we seek additional funding, we shifted our business strategy to focus our MosaiQ innovation pipeline on clinical diagnostics with testing solutions for allergy and autoimmune while pausing the development and commercialization of our MosaiQ testing solutions in immunohematology and infectious disease immunoassay screening. As we invest and reallocate resources, we reduced the number of employees, partners and costs to match the clinical diagnostics priority and seek to achieve a sustainable business.

The discussion below of our historical financial condition, results of operations and liquidity position do not reflect any effects or costs of the shift in our business strategy or the potential funding arrangements that we are currently discussing with our noteholders; therefore, these historical results are not indicative of our expected results in future periods.

**Business Overview**

We currently operate as one business segment with 432 employees in the United Kingdom, Switzerland, Dubai and the United States, as of December 31, 2022. Our principal markets are the United States, Europe and Japan. Based on the location of the customer, revenues outside the United States accounted for 44% of total revenue during the nine month period ended December 31, 2022 and 46% during the nine month period ended December 31, 2021.

We have incurred net losses and negative cash flows from operations in each year since we commenced operations in 2007. As of December 31, 2022, we had an accumulated deficit of $823.2 million. We expect our operating losses to continue for at least the remainder of the fiscal year ending March 31, 2023 as we continue our investment in the commercialization of MosaiQ. For the nine month period ended December 31, 2022, our total revenue was $27.6 million and our net loss was $98.1 million.

From our incorporation in 2012 to March 31, 2022, we have raised $160.0 million of gross proceeds through the private placement of our ordinary and preference shares and warrants, $433.0 million of gross proceeds from public offerings of our ordinary shares and issuances of ordinary shares upon exercise of warrants, $145.0 million of gross proceeds from the issuance of 12% Senior Secured Notes and $105 million of gross proceeds from the issuance of 4.75% Convertible Notes. In addition, on March 23, 2018, we raised $20.9 million from the sale and leaseback of our conventional reagents manufacturing facility near Edinburgh, Scotland, which we refer to as the Allan Robb Campus, or ARC, facility.

------

During the nine month period ended December 31, 2022, we raised gross proceeds of approximately $20.0 million from a public offering of 811,458 of our ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants exercisable for an aggregate of 855,208 ordinary shares at an exercise price of $0.04 per share after accounting for the reverse stock split.

On December 15, 2022, we raised gross proceeds of $10.0 million pursuant to the Ninth Supplemental Indenture.

As of December 31, 2022, we had available cash, cash equivalents, and investments of $27.5 million and $0.8 million of restricted cash held as part of the lease of our property in Eysins, Switzerland.

**Regulatory and Commercial Milestones**

You should read the following regulatory and commercial milestones update in conjunction with the discussion included under the sections "Item 1. Business" and "Item 1A. Risk Factors" of this report and our Annual Report on Form 10-K for the year ended March 31, 2022 filed with the SEC on June 28, 2022.

<u>Clinical diagnostics microarrays</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We currently expect commercial launch of the clinical diagnostics autoimmune microarray to occur before the end of calendar year 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We currently expect commercial launch of the clinical diagnostics allergy microarray to occur before the end of calendar year 2024.

**Revenue** 

We generate product sales revenue from the sale of conventional reagent products directly to hospitals, donor collection agencies and independent testing laboratories in the United States, the United Kingdom and to distributors in Europe and the rest of the world, and indirectly through sales to our original equipment manufacturer (or OEM) customers. We recognize revenues in the form of product sales when the goods are shipped. We also provide product development services to our OEM customers. We recognize revenue from these contractual relationships in the form of product development fees, which are included in other revenues.

Our revenue is denominated in multiple currencies. Sales in the United States and to certain of our OEM customers are denominated in U.S. Dollars. Sales in Europe and the rest of the world are denominated primarily in U.S. Dollars, Pounds Sterling or Euros. Our expenses are generally denominated in the currencies in which our operations are located, which are primarily in the United Kingdom, Switzerland and the United States. We operate globally and therefore changes in foreign currency exchange rates may become material to us in the future due to factors beyond our control.

**Cost of revenue and operating expenses** 

Cost of revenue consists of direct labor expenses, including employee benefits, overhead expenses, material costs and freight costs, along with the depreciation of manufacturing equipment and leasehold improvements. Our gross margin represents total revenue less the cost of revenue, gross margin represents gross margin expressed as a percentage of total revenue, and gross margin on product sales represents gross margin excluding other revenues as a percentage of revenues excluding other revenues. We expect our overall cost of revenue to increase in absolute U.S. Dollars as we continue to increase our product sales volumes. However, we also believe that we can achieve efficiencies in our manufacturing operations, primarily through increasing production volumes.

Our sales and marketing expenses include costs associated with our sales organization for conventional reagent products, including our direct sales force, as well as our marketing and customer service personnel and the costs of the MosaiQ commercial team. These expenses consist principally of salaries, commissions, bonuses and employee benefits, as well as travel and other costs related to our sales and product marketing activities. We expense all sales and marketing costs as incurred. We expect sales and marketing expense to increase in absolute U.S. Dollars, primarily as a result of commissions on increased product sales in the United States and as we grow the MosaiQ commercial team.

------

Our research and development expenses include costs associated with performing research, development, field trials and our regulatory activities, as well as production costs incurred in advance of the commercial launch of MosaiQ. Research and development expenses include research personnel-related expenses, fees for contractual and consulting services, travel costs, laboratory supplies and depreciation of laboratory equipment.

We expense all research and development costs as incurred, net of government grants received and tax credits. Our UK subsidiary claims certain tax credits on its research and development expenditures and these are included as an offset to our research and development expenses. Our research and development efforts are focused on developing new products and technologies for the global transfusion diagnostics market. We expect our costs associated with field trials and regulatory approvals will increase at the same time as our development costs with MosaiQ decrease. As we move to commercialization of MosaiQ in the donor testing market, we expect our overall research and development expense to decrease.

Our general and administrative expenses include costs for our executive, accounting and finance, legal, corporate development, information technology and human resources functions. We expense all general and administrative expenses as incurred. These expenses consist principally of salaries, bonuses and employee benefits for the personnel performing these functions, including travel costs. These expenses also include share-based compensation, professional service fees (such as audit, tax and legal fees), costs related to our Board of Directors, and general corporate overhead costs, which include depreciation and amortization. We expect our general and administrative expenses to increase as our business develops and also due to the costs of operating as a public company, such as additional legal, accounting and corporate governance expenses, including expenses related to compliance with the Sarbanes-Oxley Act, directors' and officers' insurance premiums and investor relations expenses.

Net interest expense consists primarily of interest charges on our Senior Secured Notes and Convertible Notes and the amortization debt discount and debt issuance costs, as well as accrued dividends on the 7% cumulative redeemable preference shares issued in January 2015. We amortize debt issuance costs over the life of the instrument and report them as interest expense in our statements of operations. Net interest also includes the expected costs of the royalty rights agreements we entered into in October 2016, June 2018, December 2018 and May 2019 with the purchasers and consenting holders, as applicable, of our Senior Secured Notes. See Note 3, "Debt" and Note 6, "Ordinary and Preference Shares" to our condensed consolidated financial statements included in this Quarterly Report for additional information.

Other income (expense), net consists of the change in fair value of our convertible debt derivative, warrant liabilities and the impact of exchange rate fluctuations. See Note 3, "Debt" and Note 5, "Fair value measurement" to our condensed consolidated financial statements included in this Quarterly Report for additional information. Exchange rate fluctuations include realized exchange fluctuations resulting from the settlement of transactions in currencies other than the functional currencies of our businesses. Monetary assets and liabilities that are denominated in foreign currencies are measured at the period-end closing rate with resulting unrealized exchange fluctuations. The functional currencies of our legal entities are Pounds Sterling, Swiss Francs, Euros, and U.S. Dollars depending on the entity.

Provision for income taxes in the three and nine month periods ended December 31, 2022 and 2021, reflected the taxes chargeable on the taxable income of our subsidiaries.

------

**Results of Operations** 

**Comparison of the Quarters ended December 31, 2022 and 2021** 

The following table sets forth, for the periods indicated, the amounts of certain components of our statements of operations and the percentage of total revenue represented by these items, showing period-to-period changes.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Quarter Ended December 31,** | **Quarter Ended December 31,** | **Quarter Ended December 31,** | **Quarter Ended December 31,** |  |  |
|  | **2022** | **2022** | **2021** | **2021** | **Change** | **Change** |
|  | **Amount** | **% of revenue** | **Amount** | **% of revenue** | **Amount** | **%** |
|  | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| **Revenue:** |  |  |  |  |  |  |
| Product sales | $9954 | 100% | $10172 | 100% | $(218) | -2% |
| Other revenues |  | 0% |  | 0% |  | 0% |
| Total revenue | 9954 | 100% | 10172 | 100% | (218) | -2% |
| Cost of revenue | 3904 | 39% | 7928 | 78% | (4024) | -51% |
| **Gross margin** | 6050 | 61% | 2244 | 22% | 3806 | 170% |
| **Operating expenses:** |  |  |  |  |  |  |
| Sales and marketing | 3298 | 33% | 2878 | 28% | 420 | 15% |
| Research and development | 15909 | 160% | 13260 | 130% | 2649 | 20% |
| General and administrative | 12394 | 125% | 17357 | 171% | (4963) | -29% |
| **Total operating expenses** | 31601 | 317% | 33495 | 329% | (1894) | -6% |
| **Operating loss** | (25551) | -257% | (31251) | -307% | 5700 | -18% |
| **Other (expense) income:** |  |  |  |  |  |  |
| Interest expense, net | (8233) | -83% | (9559) | -94% | 1326 | -14% |
| Other, net | 20591 | 207% | (3507) | -34% | 24098 | -687% |
| **Total other expense, net** | 12358 | 124% | (13066) | -128% | 25424 | -195% |
| **Loss before income taxes** | (13193) | -133% | (44317) | -436% | 31124 | -70% |
| Provision for income taxes | (131) |  | (504) |  | 373 | -74% |
| **Net loss** | $(13324) | -134% | $(44821) | -441% | $31497 | -70% |

---

Revenue

Total revenue for the quarter ended December 31, 2022 decreased by 2% to $10.0 million compared with $10.2 million for the quarter ended December 31, 2021. The decrease in product sales relates primarily to reduced orders from an OEM customer in our conventional reagent business.

Cost of revenue and gross margin

Cost of revenue decreased by 51% to $3.9 million for the quarter ended December 31, 2022 compared with $7.9 million for the quarter ended December 31, 2021. The decrease is driven primarily due to the fact there was a $2.5 million inventory write down in cost of goods sold due to inventory write-downs in the quarter ended December 31, 2021. Additionally, there were changes in estimates associated with the shift to the autoimmune business resulting in a favorable increase in gross margin of $0.6 million and a favorable impact due to foreign currency changes.

Gross margin on total revenue for the quarter ended December 31, 2022 was $6.0 million, an increase of 170% when compared with a $2.2 million profit for the quarter ended December 31, 2021. Total gross margin on sales was 61% in the quarter ended December 31, 2022 compared to 22% in the quarter ended December 31, 2021.

Sales and marketing expenses

Sales and marketing expenses were $3.3 million for the quarter ended December 31, 2022, compared with $2.9 million for the quarter ended December 31, 2021. This increase was attributable primarily to restructuring costs of $0.3 million during the quarter ended December 31, 2022. As a percentage of total revenue, sales and marketing expenses were 33% for the quarter ended December 31, 2022 compared to 28% for the quarter ended December 31, 2021.

Research and development expenses

Research and development expenses increased by 20% to $15.9 million for the quarter ended December 31, 2022 compared with $13.3 million for the quarter ended December 31, 2021. The increase in research and development expenses is driven by $2.4 million in restructuring costs associated with the change in strategy to autoimmune products which took place during the quarter.

General and administrative expenses

General and administrative expenses decreased by 29% to $12.4 million for the quarter ended December 31, 2022, compared with $17.4 million for the quarter ended December 31, 2021. The decrease was primarily attributed to a decrease of stock compensation

------

expense in the period where we recognized $0.9 million in the quarter ended December 31, 2022 compared with $2.3 million in the quarter ended December 31, 2021. Additionally, in the quarter ended December 31, 2021 there were one-time executive management costs of associated with new hires and relocation which were not repeated in the current year. As a percentage of total revenue, general and administrative expenses were 125 % for the quarter ended December 31, 2022 compared to 171% for the quarter ended December 31, 2021.

Other income (expense)

Net interest expense was $8.2 million for the quarter ended December 31, 2022 compared with $9.6 million in interest expense for the quarter ended December 31, 2021. Interest expense in the quarter ended December 31, 2022 included $5.3 million of interest expense on our Senior Secured Notes and royalty liabilities compared with $6.8 million expense for the quarter ended December 31, 2021. The decrease in interest expense in the quarter ended December 31, 2022 is primarily due to a reduction in interest expense of $1.4 million associated with the royalty rights agreement compared to the prior year. Interest expense related to the Convertible Notes was included $2.6 million and $2.5 million for the quarter ended December 31, 2022 and 2021 respectively. Net interest expense also included $0.3 million of dividends accrued on the 7% cumulative redeemable preference shares in each of the quarters ended December 31, 2022 and December 31, 2021.

Other, net was a $20.6 million gain for the quarter ended December 31, 2022 compared with a $3.5 million loss for the quarter ended December 31, 2021. For the quarter ended December 31, 2022 this comprised a $2.6 million gain related to the change in fair value associated with derivative liabilities, a $0.1 million gain related to a reduction of impairment on one CSAM fund and $17.9 million in foreign exchange gains arising on monetary assets and liabilities denominated in foreign currencies. For the quarter ended December 31, 2021 this comprised a $3.3 million loss related to the change in fair value associated with derivative liabilities and $0.2 million in foreign exchange losses arising on monetary assets and liabilities denominated in foreign currencies

Provision for income taxes

Provision for income taxes in the quarter ended December 31, 2022 and 2021, reflected the taxes chargeable on the taxable income of our subsidiaries.

**Comparison of the Nine Month Periods ended December 31, 2022 and 2021**

The following table sets forth, for the periods indicated, the amounts of certain components of our statements of operations and the percentage of total revenue represented by these items, showing period-to-period changes.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine months ended December 31,** | **Nine months ended December 31,** | **Nine months ended December 31,** | **Nine months ended December 31,** |  |  |
|  | **2022** | **2022** | **2021** | **2021** | **Change** | **Change** |
|  | **Amount** | **% of revenue** | **Amount** | **% of revenue** | **Amount** | **%** |
|  | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| **Revenue:** |  |  |  |  |  |  |
| Product sales | $27624 | 100% | $28497 | 99% | $(873) | -3% |
| Other revenues |  | 0% | 231 | 1% | (231) | -100% |
| Total revenue | 27624 | 100% | 28728 | 100% | (1104) | -4% |
| Cost of revenue | 31141 | 113% | 17579 | 61% | 13562 | 77% |
| Gross margin | (3517) | -13% | 11149 | 39% | (14666) | -132% |
| **Operating expenses:** |  |  |  |  |  |  |
| Sales and marketing | 10117 | 37% | 8011 | 28% | 2106 | 26% |
| Research and development | 44316 | 160% | 42545 | 148% | 1771 | 4% |
| General and administrative | 31127 | 113% | 37555 | 131% | (6428) | -17% |
| Total operating expenses | 85560 | 310% | 88111 | 307% | (2551) | -3% |
| Operating (loss) | (89077) | -322% | (76962) | -268% | (12115) | 16% |
| **Other income (expense):** |  |  |  |  |  |  |
| Interest expense, net | (9421) | -34% | (21914) | -76% | 12493 | -57% |
| Other, net | 1011 | 4% | 677 | 2% | 334 | 49% |
| Total other expense, net | (8410) | -30% | (21237) | -74% | 12827 | -60% |
| Loss before income taxes | (97487) | -353% | (98199) | -342% | 712 | -1% |
| Provision for income taxes | (631) |  | (1019) |  | 388 | -38% |
| Net loss | $(98118) | -355% | $(99218) | -345% | $1100 | -1% |

---

Revenue

Total revenue for the nine month period ended December 31, 2022 decreased by 4% to $27.6 million, compared with $28.7 million for the nine month period ended December 31, 2021.

------

The decrease in product sales relates primarily to reduced orders from an OEM customer in our conventional reagent business. Other revenues for the nine month period ended December 31, 2021 related to a small development project for an OEM customer.

Cost of revenue and gross margin

Cost of revenue increased by 77% to $31.1 million for the nine month period ended December 31, 2022, compared with $17.6 million for the nine month period ended December 31, 2021. The increase in costs of revenue resulted from a $15.3 million write-down of transfusion related MosaiQ inventory and purchase commitments compared to a $2.5 million write down of inventory in the period ended December 31, 2022. There were also higher costs in our conventional reagent business due to inventory write-downs and write-offs of certain products due to expiration of products and quality control tests, higher production costs associated with inflation, and higher costs associated with sales mix in the nine month period ended December 31, 2022.

Gross margin on total revenue for the nine month period ended December 31, 2022 was a $3.5 million loss, compared with $11.1 million gross margin for the nine month period ended December 31, 2021.

Sales and marketing expenses

Sales and marketing expenses were $10.1 million for the nine month period ended December 31, 2022, compared with $8.0 million for the nine month period ended December 31, 2021. This increase was attributable to greater personnel and other expenses related to commercial launch activities with MosaiQ, opening of a sales office in the Middle-East, and restructuring costs associated with the change in strategy to autoimmune products. As a percentage of total revenue, sales and marketing expenses were 37% for the nine month period ended December 31, 2022 compared to 28% for the nine month period ended December 31, 2021.

Research and development expenses

Research and development expenses increased by 4% to $44.3 million for the nine month period ended December 31, 2022, compared with $42.5 million for the nine month period ended December 31, 2021. The increase in research and development expenses in 2022, is driven by the $2.4 million in restructuring costs associated with the Company's change in strategy to focus on autoimmune products and offset by a payment of $1.5 million related to the costs of our intellectual property license with TTP which were incurred in 2021 but did not occur in 2022. This was offset by higher expenses related to additional employee and third party expenses to support planned field trials and product development at the start of the fiscal year.

General and administrative expenses

General and administrative expenses decreased by 17% to $31.1 million for the nine month period ended December 31, 2022, compared with $37.6 million for the nine month period ended December 31, 2021. The decrease is primarily driven by a reduction in stock compensation expense which was $2.6 million in the nine month period ended December 31, 2022 compared with $5.5 million in the nine month period ended December 31, 2021. Additionally, in the quarter ended December 31, 2021 there were one-time executive management costs of associated with new hires and relocation which were not repeated in the current year. As a percentage of total revenue, general and administrative expenses were 113% for the nine month period ended December 31, 2022 and 131% for the nine month period ended December 31, 2021.

Other income (expense)

Net interest expense was $9.4 million for the nine month period ended December 31, 2022, compared with $21.9 million for the nine month period ended December 31, 2021. Interest expense in the nine month period ended December 31, 2022 included $0.8 million of interest income on our Senior Secured Notes and royalty liabilities compared with $15.3 million in expense the nine month period ended December 31, 2021. The decreased expense reflected changes in the royalty cost estimates. Interest expense for the nine month period ended December 31, 2022 also included $7.8 million of interest charges related to the Convertible Notes compared to $6.0 million for the nine month period ended December 31, 2021. Net interest expense also included $0.8 million of dividends accrued on the 7% cumulative redeemable preference shares in each of the nine month periods ended December 31, 2022 and December 31, 2021. In addition, in the nine month period ended December 31, 2021 we realized interest income of $0.2 million on our short-term money market investments while no interest income was recognized in the nine month period ended December 31, 2022.

Other, net represented a gain of $1.0 million for the nine month period ended December 31, 2022, compared with a $0.7 million gain for the nine month period ended December 31, 2021. For the nine month period ended December 31, 2022 this comprised a $15.5 million gain related to the change in fair value associated with the Convertible Loan derivatives and warrants, $13.4 million of foreign exchange losses arising on monetary assets and liabilities denominated in foreign currencies, and a $1.1 million impairment related to the change in estimated fair value of CSAM funds. For the nine month period ended December 31, 2021 this comprised a $3.9 million gain related to the change in fair value of derivatives liabilities and $3.2 million of foreign exchange losses arising on monetary assets and liabilities denominated in foreign currencies

Provision for income taxes

------

Provision for income taxes in the nine month period ended December 31, 2022 and 2021 reflected the taxes payable on the taxable income of our subsidiaries.

**Quarterly Results of Operations** 

Our quarterly product sales can fluctuate depending upon the shipment cycles for our red blood cell-based products, which account for approximately two-thirds of our current product sales. For these products, we typically experience 13 shipping cycles per year. This equates to three shipments of each product per quarter, except for one quarter per year when four shipments occur. Not all products ship on the same day so quarters where four shipments occur do not always align. In fiscal 2022 we experienced additional shipments in the third and fourth quarters. In fiscal 2023, the greatest impact of extra product shipments is expected to occur in our third quarter. The timing of shipment of bulk antisera products to our OEM customers may also move revenues from quarter to quarter. We also experience some seasonality in demand around holiday periods in both Europe and the United States. As a result of these factors, we expect to continue to see seasonality and quarter-to-quarter variations in our product sales.

The timing of product development fees included in other revenues is mostly dependent upon the achievement of pre-negotiated project milestones.

**Liquidity and Capital Resources** 

See "Updates on Liquidity, Financial Condition and Company Strategy" above for a discussion of recent developments affecting our current and expected liquidity and capital resources.

Since our commencement of operations in 2007, we have incurred net losses and negative cash flows from operations. As of December 31, 2022, we had an accumulated deficit of $823.2 million. During the nine month period ended December 31, 2022, we incurred a net loss of $98.1 million and used $89.2 million of cash in operating activities. As described under results of operations, our use of cash during the nine month period ended December 31, 2022 was primarily attributable to our investment in the development of MosaiQ and corporate costs, including costs related to being a public company.

From our incorporation in 2012 to March 31, 2022, we have raised $160.0 million of gross proceeds through the private placement of our ordinary and preference shares and warrants, $433.0 million of gross proceeds from public offerings of our ordinary shares and issuances of ordinary shares upon exercise of warrants, $145.0 million of gross proceeds from the issuance of the Senior Secured Notes and $105 million of gross proceeds from the issuance of the Convertible Notes. In addition, on March 23, 2018, we raised $20.9 million from the sale and leaseback of the Allan Robb Campus.

During the nine month period ended December 31, 2022, we raised gross proceeds of approximately $20.0 million from a public offering of 811,458 of our ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants exercisable for an aggregate of 855,208 ordinary shares at an exercise price of $0.04 per share.

On December 15, 2022, the Company received gross proceeds of $10.0 million pursuant to the Ninth Supplemental Indenture. See Note 3, "Debt" for addtional information about modifications to our debt agreements during the period.

**Cash Flows for the quarter ended December 31, 2022 and 2021**

Operating activities

Net cash used in operating activities was $89.3 million during the nine month period ended December 31, 2022, which included net losses of $98.1 million offset by non-cash items of $8.4 million. Non-cash items were depreciation and amortization expense of $4.3 million, share-based compensation expense of $2.6 million, a decrease from the change in fair value of loan derivatives of $15.6 million, Swiss pension costs of $0.6 million, amortization of debt discounts, royalty, and unrealized foreign currency loss on debt of $13.0 million, impairment of investments of $1.2 million, accrued preference share dividends of $0.8 million, deferred lease rentals of $0.9 million and income taxes of $0.6 million. We also experienced a net cash outflow of $0.5 million from changes in operating assets and liabilities during the period, consisting of a $1.4 million increase in accrued compensation and benefits, a $6.6 million decrease in inventories, a decrease from a $9.0 million from a net change in other assets and liabilities, a $2.3 million reduction in accounts payable and accrued liabilities, and a $0.8 million increase in accounts receivables.

Net cash used in operating activities was $96.2 million during the nine month period ended December 31, 2021, which included net losses of $99.2 million offset by non-cash items of $15.8 million. Non-cash items were depreciation and amortization expense of $5.7 million, share-based compensation expense of $4.7 million, a reduction from the change in fair value of loan derivatives of $3.9 million, Swiss pension costs of $0.5 million, amortization of deferred debt issue costs and discounts of $6.4 million, accrued preference share dividends of $0.8 million, deferred lease rentals of $0.5 million and income taxes of $1.1 million. We also experienced a net cash outflow of $12.7 million from changes in operating assets and liabilities during the period, consisting of a $5.2 million reduction in accrued compensation and benefits, a $0.5 million increase in inventories, a $2.3 million increase in other assets, a $3.8 million reduction in accounts payable and accrued liabilities and a $0.9 million increase in accounts receivables.

------

Investing activities

Net cash provided by investing activities was $0.9 million for the nine month period ended December 31, 2022 compared to $44.6 million for the quarter ended December 31, 2021. We spent $1.7 million on purchases of property and equipment in the nine month period ended December 31, 2022, which was mainly related to purchasing MosaiQ instruments and investments in our IT infrastructure. We also received distributions on our short-term money market investments of $2.6 million from CSAM in the nine month period ended December 31, 2022.

Net cash provided by investing activities was $44.6 million for the nine month period ended December 31, 2021. We spent $2.3 million on purchases of property and equipment in the nine month period ended December 31, 2021, which was mainly related to purchasing MosaiQ instruments and investments in our IT infrastructure. We also received distributions on our short-term money market investments of $31.9 million from CSAM in the nine month period ended December 31, 2021, received $19.5 million from selling other short term investments and invested $4.5 million in other short-term money market investments.

Financing activities

Net cash provided by financing activities was $27.5 million during the nine month period ending December 31, 2022, consisting of $17.9 million of proceeds related to the issuance of ordinary shares and warrants after deducting issuance costs, $10.0 million related to proceeds from the further SSNs and $0.5 million of cash spent on repayments on finance leases.

Net cash provided by financing activities was $87.8 million during the quarter ended December 31, 2021, consisting of $100.5 million generated from the issuance of the Convertible Notes, net of debt issue costs, offset by $12.1 million repayment of the Senior Secured Notes, expenses related to restricted stock units vested of $0.1 million and $0.5 million of repayments on finance leases.

**Operating and Capital Expenditure Requirements**

We have not achieved profitability on an annual basis since we commenced operations in 2007 and we expect our operating losses to continue for at least the remainder of the fiscal year ending March 31, 2023. As we continue MosaiQ development, we expect our operating expenses during the year ended March 31, 2023 to be similar to those of the year ended March 31, 2022.

As of December 31, 2022, we had $27.5 million of available cash, cash equivalents, and investments and $0.8 million of restricted cash held as part of the arrangements relating to the lease of our properties in Eysins, Switzerland.

**Critical Accounting Policies and Significant Judgments and Estimates**

We have prepared our condensed consolidated financial statements in accordance with U.S. GAAP. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

For a detailed discussion of our critical accounting policies, see Note 1, "Organization and Summary of Significant Accounting Policies." to our Annual Report on Form 10-K for the year ended March 31, 2022. For a detailed description of our significant judgements and estimates, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended March 31, 2022.

**Recent Accounting Pronouncements** 

We did not adopt any other new accounting pronouncements during the nine month period ended December 31, 2022 that had a significant effect on our condensed consolidated financial statements included in this Quarterly Report.

**Item 3. Reserved**

**Item 4. Controls and Procedures**

**Evaluation of disclosure controls and procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and is accumulated and

------

communicated to our management, including our Chief Executive and Chief Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

**PART II – OTHER INFORMATION** 

**Item 1. Legal Proceedings** 

We are not currently party to any pending legal or governmental proceedings that we believe could have a material adverse effect on our business or financial condition. However, we may be subject to various claims and legal actions arising in the ordinary course of business from time to time.

**Item 1A. Risk Factors** 

**We are subject to the risks and uncertainties associated with proceedings under chapter 11 of the Bankruptcy Code.**

On the January 10, 2023, the Company filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. On January 9, 2023, the Company entered into the A&R TSA with holders of all of its (i) Senior Secured Notes issued under the Senior Secured Notes Indenture, by and among the Company, the guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee, and (ii) Convertible Notes issued under Convertible Notes Indenture, by and among the Company, the guarantors party thereto, and Wilmington Savings Fund Society, FSB, as trustee. On the January 10, 2023, the Company filed the Plan and the related disclosure statement, in accordance with the terms of A&R TSA.

For the duration of our bankruptcy proceedings, our operations and our ability to develop and execute our business plan, as well as our continuation as a going concern thereafter, are subject to risks and uncertainties associated with bankruptcy and the implementation of the restructuring transactions, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to consummate the Plan and the restructuring transactions contemplated under the A&R TSA;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to maintain our relationships with our suppliers, service providers, employees and other third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to retain key employees; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the actions and decisions of our creditors and other third parties who have interests in our bankruptcy proceedings.

Delays in our bankruptcy proceedings and implementing our restructuring transactions increase our costs associated with the bankruptcy process along with the risks of our being unable to reorganize our business and emerge from bankruptcy.

These risks and uncertainties could affect our business and operations in various ways. Pursuant to the Bankruptcy Code, we need the prior approval of the Bankruptcy Court for transactions outside the ordinary course of business, which may limit our ability to respond timely to certain events or take advantage of certain opportunities. We cannot accurately predict or quantify the ultimate impact that events that occur during our bankruptcy proceedings will have on our business, financial condition, results of operations and cash flows.

Even if the Plan is consummated, we will continue to face a number of risks, including our ability to reduce expenses, implement any strategic initiatives and generally maintain favorable relationships with and secure the confidence of our counterparties. Accordingly, while we believe that the Plan places us in the best position for success as a going concern, we cannot provide assurance that the proposed financial restructuring will allow us to continue as a going concern.

**The Plan may not become effective.**

The Plan may not become effective because it is subject to the satisfaction of certain conditions precedent (some of which are beyond our control). There can be no assurance that such conditions will be satisfied or waived and, therefore, that the Plan will become effective and that we will emerge from our bankruptcy proceedings as contemplated by the Plan. If the effective date of the Plan is delayed, we may not have sufficient cash available to operate our business. There is no assurance of the terms on which such financing may be available or if such financing will be available at all. If the transactions contemplated by the Plan are not completed, it may become necessary to amend the Plan, with accompanying expenses and material delays.

**We have substantial liquidity needs and may not have sufficient liquidity for the time necessary to consummate the Plan.**

We have incurred, and expect to continue to incur, significant costs in connection with our bankruptcy proceedings. While we believe that we will have sufficient liquidity, including cash on hand and funds generated from ongoing operations, to fund anticipated cash requirements through our bankruptcy proceedings, there can be no assurance that our current liquidity will be sufficient to allow us to satisfy our obligations related to our bankruptcy proceedings and those necessary for consummation of the Plan.

**Even if the Plan is consummated, we may not be able to achieve our stated goals and continue as a going concern.**

------

Even if the Plan is consummated, we will continue to face a number of risks, including decreased market demand or increasing expenses. Accordingly, we cannot guarantee that the Plan or any other chapter 11 plan of reorganization will achieve our stated goals. Furthermore, even if our debts are discharged through such plan, we may need to raise additional funds through public or private debt or equity financing to fund the Company's operations and its capital needs. Our access to additional financing is, and for the foreseeable future will likely continue to be, extremely limited, if it is available at all. Therefore, adequate funds may not be available when needed, or in sufficient amounts or available on acceptable terms, if at all.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds** 

None.

**Item 3. Defaults Upon Senior Securities** 

None.

**Item 4. Mine Safety Disclosures** 

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits** 

The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q:

---

| | |
|:---|:---|
| Exhibit No. | Description |
| <br>4.1 | <br>[<u>Eighth Supplemental Indenture, dated as of November 21, 2022, by and among the Company, the Guarantors party thereto and U.S. Bank National Association, as trustee and collateral agent (filed as Exhibit 4.1 on Form 8-K on November 22, 2022 and incorporated herein by reference)</u>](https://www.sec.gov/Archives/edgar/data/1596946/000119312522291252/d425605dex41.htm) |
| <br>4.2 | <br>[<u>Ninth Supplemental Indenture, dated as of December 15, 2022, by and among the Company, the guarantors party thereto and U.S. Bank National Association, as trustee and collateral agent (filed as Exhibit 4.1 on Form 8-K on December 19 2022 and incorporated herein by reference)</u>](https://www.sec.gov/Archives/edgar/data/1596946/000119312522307937/d414069dex41.htm) |
| <br>4.3 | <br>[<u>Fourth Supplemental Indenture, dated as of January 4, 2023, by and among the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee (filed as Exhibit 4.1 on Form 8-K on January 9, 2023 and incorporated herein by reference)</u>](https://www.sec.gov/Archives/edgar/data/1596946/000119312523004865/d370479dex41.htm) |
| <br>10.1† | <br>[<u>Transaction Support Agreement, dated as of December 5, 2022, by and among the Company and the Consenting Noteholders (filed as Exhibit 10.1 on Form 8-K on December 7, 2022 and incorporated herein by reference)</u>](https://www.sec.gov/Archives/edgar/data/1596946/000119312522300271/d431926dex101.htm) |
| <br>10.2† | <br>[<u>Amended and Restated Transaction Support Agreement, dated as of January 9, 2023, by and among the Company and the Consenting Noteholders (filed as Exhibit 10.1 on Form 8-K on January 10, 2023 and incorporated herein by reference)</u>](https://www.sec.gov/Archives/edgar/data/1596946/000119312523005670/d165499dex101.htm) |
| <br>10.3† | <br>[<u>Omnibus Transaction Agreement, dated as of January 9, 2023, by and among the Company and the Convertible Noteholders(filed as Exhibit 10.2 on Form 8-K on January 10, 2023 and incorporated herein by reference)</u>](https://www.sec.gov/Archives/edgar/data/1596946/000119312523005670/d165499dex102.htm) |
| <br>31.1 | <br>[<u>Certification of Manuel O. Méndez, Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](ck0001596946-ex31_1.htm) |
| <br>31.2 | <br>[<u>Certification of Ali Kiboro, Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](ck0001596946-ex31_2.htm) |
| <br>32.1 | <br>[<u>Certification of Manuel O. Méndez, Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>](ck0001596946-ex32_1.htm) |
| <br>32.2 | <br>[<u>Certification of Ali Kiboro, Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>](ck0001596946-ex32_2.htm) |
| <br>101 | <br>The following financial information from Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 filed with the SEC, formatted in Inline eXtensible Business Reporting Language (Inline XBRL): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iii) Condensed Consolidated Statements of Changes in Shareholders' Deficit (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited) and (v) Notes to Condensed Consolidated Financial Statements.  |

---

------

---

| | |
|:---|:---|
| <br>104<br>| <br>Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101). |
| † | Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential, in compliance with Regulation S-K Item 601(b)(10). |

---

------

 **SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | QUOTIENT LIMITED |
| Date: February 9, 2023 | /s/ Manuel O. Méndez |
|  | Manuel O. Méndez <br>Chief Executive Officer  |

---

---

| | |
|:---|:---|
| Date: February 9, 2023 | /s/ Ali Kiboro |
|  | Ali Kiboro<br>Chief Financial Officer  |

---

------

## Exhibit 31.1

**Exhibit 31.1** 

**CERTIFICATION** 

I, Manuel O. Méndez, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Quotient Limited;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 9, 2023 | /s/ Manuel O. Méndez |
|  | Manuel O. Méndez |
|  | Chief Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2** 

**CERTIFICATION** 

I, Ali Kiboro, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Quotient Limited;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 9, 2023 | /s/ Ali Kiboro |
|  | Ali Kiboro |
|  | Chief Financial Officer |

---

------

## Exhibit 32.1

**Exhibit 32.1** 

**CERTIFICATION**

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Quotient Limited, a company incorporated under the laws of Jersey, Channel Islands (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report for the quarter ended December 31, 2022 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: February 9, 2023 | /s/ Manuel O. Méndez |
|  | Manuel O. Méndez |
|  | Chief Executive Officer |

---

This certification is being furnished and not filed, and shall not be incorporated into any document for any purpose, under the Securities Exchange Act of 1934 or the Securities Act of 1933.

------

## Exhibit 32.2

**Exhibit 32.2** 

**CERTIFICATION** 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Quotient Limited, a company incorporated under the laws of Jersey, Channel Islands (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report for the quarter ended December 31, 2022 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: February 9, 2023 | /s/ Ali Kiboro |
|  | Ali Kiboro |
|  | Chief Financial Officer |

---

This certification is being furnished and not filed, and shall not be incorporated into any document for any purpose, under the Securities Exchange Act of 1934 or the Securities Act of 1933.

------